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ABSTRACT 
 
Upon activation by the platelet-derived growth factor receptor (PDGFR), 
phosphatidylinositol 3'-kinase (PI3K) converts phosphatidylinositol 4,5-bisphosphate to 
phosphatidylinositol 3,4,5-trisphosphate to activate the PI3K/Akt cellular survival signalling 
pathway within cells.  The p85 subunit of PI3K has also been shown to have GTPase activating 
protein (GAP) activity towards Rab proteins involved in receptor endocytosis and trafficking, 
specifically Rab5 and Rab4.  Rab5 is responsible for regulating the fusion of vesicles containing 
activated receptors to traffic them to intracellular early/sorting endosomes.  Rab4 is responsible 
for regulating the exit of receptors to a recycling pathway back to the plasma membrane.  The 
p85 RabGAP activity is responsible for deactivating Rab5 and Rab4 function by accelerating 
their GTPase activity, resulting in the inactive conformation of Rab5 and Rab4, and decreased 
vesicle fusion events during receptor trafficking.  The work in this thesis was performed to 
understand how p85 interacts with, and regulates, Rab5 and Rab4. Glutathione S-transferase 
pulldown experiments showed the p85 protein was able to interact with Rab5 through its BH 
domain and another unidentified domain.  Cells expressing a p85-R274A mutant defective for 
RabGAP activity displayed increased PDGFR activation and decreased degradation.  To 
understand the mechanism of decreased PDGFR degradation, PDGFR immunoprecipitation 
experiments showed the PDGFR was ubiquitinated, a signal needed for multi-vesicular body 
sorting.  Biotinylation experiments showed the PDGFR was being more rapidly endocytosed and 
then sequestered within the cell.  Immunofluorescence experiments showed cells expressing the 
p85-R274A mutant clearly altered PDGFR trafficking during receptor endocytosis.  These results 
suggest the PDGFR was not spending longer periods of time on the cell surface to continue 
signalling and was not lacking the modification needed to be sorted to a degradative pathway.  
The defective trafficking observed in p85-R274A expressing cells, over time, may block PDGFR 
trafficking, which prevents normal PDGFR dephosphorylation and degradation, and could be 
attributed to a lack of sufficient cytosolic Rab5-GDP and Rab4-GDP required to associate with 
new membranes and facilitate additional vesicle fusion events.  The lack of lysosomal targeting 
allows the receptor to be sequestered in cells, but still have the ability to signal as the receptor 
would not be targeted to multi-vesicular bodies where signalling is abolished. 
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INTRODUCTION 
1.1 Receptor tyrosine kinases (RTK) and signalling 
Receptor tyrosine kinases (RTK) are involved in several cellular signalling pathways 
that regulate key cell signalling functions like proliferation, differentiation, and apoptosis (Gavi 
et al., 2006).  RTK pathways are no longer considered linear pathways. They are now viewed 
as intricate signalling networks which contain modules of multi-protein complexes that 
assemble at various intracellular compartments to process, integrate and transmit information.  
These signals ultimately specify a particular biological response (McKay and Morrison, 2007).  
The receptor is at the head of these pathways and is the gateway between the extracellular 
matrix and the inside of the cell.   
RTKs consist of an extracellular ligand binding domain, a transmembrane domain and 
an intracellular catalytic domain (Gavi et al., 2006).  They are classified as such because they 
contain an intrinsic tyrosine kinase activity. The receptors dimerize after ligand binding and 
become active by autophosphorylation on tyrosine residues.  These phosphotyrosine (pTyr or 
pY) residues generally serve two purposes: i) to regulate the kinase activity of the receptor and; 
ii) to create binding sites for downstream signalling molecules.  Thus, through the receptor 
itself and adaptor proteins, numerous signalling components are recruited to the cell surface, 
thereby activating the repertoire of effector cascades required for a specific response within the 
cell (Claesson-Welsh, 1994a). 
RTKs are classified into more than 16 subfamilies which are grouped by receptor 
structure (Alvarez et al., 2006).  The insulin receptor, vascular endothelial growth factor 
receptor, epidermal growth factor receptor (EGFR) and platelet-derived growth factor (PDGF) 
receptor (PDGFR) are a few prototypical growth factor receptors representing four of the 
different RTK subfamilies.  The EGFR is the most well-studied but the PDGFR has been 
shown to display signalling analogous to the EGFR.  For the purpose of this thesis, the focus 
will be on the PDGFR and the pathways it regulates. 
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1.2 PDGF ligands and receptors 
 The PDGFR family consists of two receptors: PDGFR! and PDGFR".  The PDGFR! is 
170 kDa and the PDGFR" is 180 kDa.  Both receptors are structurally-related transmembrane 
glycoproteins that contain N-linked and O-linked glycosylations.  The extent of glycosylation 
varies between different cell types (Heldin et al., 1988).  Both receptors contain an extracellular 
region consisting of five immunoglobulin (Ig)-like domains, a single transmembrane segment, 
a juxtamembrane segment, a protein-tyrosine kinase domain separated by a kinase insert 
region, and a carboxy-terminal tail (Fig. 1.1) (Heldin and Westermark, 1999; Wang et al., 
2004).  Unique to these receptors is a 100 amino acid (aa) non-catalytic sequence dividing its 
protein-tyrosine kinase domain into two parts.  The overall aa identity between the different 
parts of the ! and " receptors are also indicated in Fig. 1.1 (Claesson-Welsh, 1994b).  The 
PDGFR! and the PDGFR" are induced to dimerize and form homo- or heterodimers: !!, !", 
and "".  The dimers produced are dependent on the specific PDGF ligands (see below) that 
bind the three N-terminal Ig-like domains on the receptors (Bornfeldt et al., 1995; Claesson-
Welsh, 1994a; Heidaran et al., 1990; Shih and Holland, 2006).   
PDGF is synthesized in the !-granules of platelets.  Upon platelet stimulation, PDGF is 
released and stimulates the proliferation of arterial smooth muscles, fibroblasts, and glial cells 
(Linder et al., 1979).  The PDGF family consists of four ligands A-D.  A and B were 
discovered first (Heldin et al., 1985) and C and D were discovered later (LaRochelle et al., 
2001; Li et al., 2000). The PDGF ligands form dimers joined by disulfide bonds.  There are 
five different PDGF dimers: AA, AB, BB, CC, and DD.  AA, AB, and BB are secreted in an 
active form whereas CC and DD are secreted in an inactive form and must first be cleaved to 
become active (Tallquist and Kazlauskas, 2004).  The active form of each dimer selectively 
binds the PDGFR! and the PDGFR" homo- or heterodimers with different affinities (Fig. 1.2).  
The PDGFR!! homodimer binds PDGF-AA, PDGF-AB, PDGF-BB and PDGF-CC.  The 
PDGFR!" heterodimer binds PDGF-AB, PDGF-BB, PDGF-CC and PDGF-DD.  The 
PDGFR"" homodimer binds PDGF-BB and PDGF-DD.  The PDGF-BB is the universal ligand 
as it is able to bind to all homo- and heterodimer PDGFRs and is the only ligand used in this 
thesis.  PDGFR activation is stimulated by ligand binding.    
Extracellular Domain
Juxtamembrane segment
Tyrosine Kinase Domain
(N-terminal domain)
Kinase insert region
Tyrosine Kinase Domain
(C-terminal domain)
Carboxy-terminal tail
PDGFR! PDGFR"
Amino Acid
Identity (%)
30
83
87
35
74
27
Fig. 1.1.  Structure and overall amino acid identity between the different domains
of the PDGFR.   PDGFR! and PDGFR" contain an extracellular region consisting of
five immunoglobulin-like domains, a single transmembrane segment, a
juxtamembrane segment, a protein-tyrosine kinase domain seperated by a 100 aa non-
catalytic kinase insert region and a carboxy-terminal tail. (Adapted from Heldin and
Westermark, 1999 and Claesson-Welsh, 1994b)
extracellular
matrix
cytoplasm
3
Fig. 1.2. PDGF ligand and receptor interactions. The PDGFR!! homodimer
binds PDGF-AA, PDGF-AB, PDGFR-BB and PDGF-CC.  The PDGFR!"
heterodimer binds PDGF-AB, PDGFR-BB, PDGF-CC and PDGF-DD.  The
PDGFR"" homodimer binds PDGF-BB and PDGF-DD.
!"!! ""
AA AB BB CC DD
cytoplasm
extracellular matrix
Plasma membrane
4
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Ligand binding to the PDGFR induces receptor dimerization.   Dimerization activates 
the intrinsic kinase activity of the receptors and the receptors are able to autophosphorylate on 
specific tyrosine residues thereby becoming more active.  This autophosphorylation is known 
as trans-phosphorylation.  Phosphorylation of Tyr 857 of the PDGFR" and Tyr 849 of the 
PDGFR! has been shown to be the key steps critical for full enzymatic activation of the 
receptors (Claesson-Welsh, 1994b).  There are several Tyr residues that are phosphorylated.  
The pTyr residues act as binding sites for signal transduction molecules which contain Src 
homology 2 (SH2) domains and/or pTyr binding (PTB) domains and which are then able to 
transduce signalling information cascades to the cell.   
The PDGFR! and the PDGFR" are expressed at variable levels in different cell types 
(Table 1.1) and elicit similar cellular effects (Table 1.2) (Alvarez et al., 2006).  This thesis uses 
NIH 3T3 mouse fibroblast cells, and although fibroblasts express both the ! and " PDGFR, 
they generally express higher levels of PDGFR" (Alvarez et al., 2006).  Due to this, PDGFR" 
was used in the immunoprecipitation studies.  Currently there have been several pTyr residues 
within the PDGFR" identified which are known binding sites for specific effector molecules 
(Fig. 1.3) (Claesson-Welsh, 1994a).  Several effector molecules include:  i) Src Tyr kinase 
which binds to pTyr579 and 581; ii) Src homologous and collagen-like (SHC) adaptor protein 
binds pTyr 579, 740, 751, and 771; iii) the adaptor protein growth factor receptor-bound 
protein 2 (Grb2) binds pTyr 716; iv) the adaptor protein Nck binds pTyr 751 and; v) 
phosphatidylinositol 3'-kinase (PI3K) which converts phosphatidylinositol 4,5-bisphosphate 
(PI4,5P2) to phosphatidylinositol 3,4,5-trisphosphate (PI3,4,5P3) and binds pTyr 740 and 751; 
vi) the GAP protein which stimulates the hydrolysis of Ras-coupled GTP and binds pTyr 771; 
vii) phosphotyrosine phosphatase 1D (PTP1D) binds pTyr 1009; and viii) phospholipase C-# 
(PLC-#) which hydrolyses PI4,5P2 and binds pTyr 1009 and 1021.  The binding of these 
effector molecules activate distinct signalling cascades throughout the cell (Claesson-Welsh, 
1994a).   
The PDGFR is one of many RTKs responsible for controlling numerous cellular 
processes such as proliferation, differentiation, and cell survival (Schlessinger, 2000).  For the 
purpose of this thesis, there are two main pathways regulated by the PDGFR which will  
Table 1.1.  Types of cells that express PDGFR! and PDGFR"
Cell Types PDGFR! PDGFR"
Platelets YES -
Fibroblasts YES YES
Pericytes YES YES
Vascular smooth muscle cells YES YES
Neurons YES YES
Mammary epithelial cells - YES
Myeloid hematopoietic cells - YES
Macrophages - YES
Kidney mesangial cells YES YES
Liver cells - YES
Myoblasts YES -
Adapted from Alverez et al., 2006
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Table 1.2.  PDGFR biological responses
Adapted from Claesson-Welsh, 1994a
Biological Response PDGFR! PDGFR"
Turnover of phosphatidylinositols and inositol
phosphatases
YES YES
Calcium fluxes YES YES
Membrane ruffles, cytoskeletal rearrangements YES YES
Migration YES
Cell type
dependent
YES
Proliferation YES YES
Angiogenesis - YES
Timing of differentiation YES -
7
579
581
716
740
751
771
857
1009
1021
GAP
PLC#
Src
PI3K
Grb2
SHC
Nck
PTP1D
Full Kinase Activity
Fig. 1.3. PDGFR" phosphotyrosine binding sites for known effector
molecules. Src Tyr kinase which binds to pTyr579 and 581.  Src homologous and
collagen-like (SHC) adaptor protein binds pTyr 579, 740,751, and 771.  The
adaptor protein growth factor receptor-bound protein 2 (Grb2) binds pTyr 716.
The adaptor protein Nck binds pTyr 751.  Phosphatidylinositol 3'-kinase (PI3K)
binds pTyr 740 and 751.  The GAP protein stimulates the hydrolysis of Ras-
coupled GTP and binds pTyr 771.  Phosphotyrosine phosphatase 1D (PTP1D)
binds pTyr 1009, and phospholipase C-# (PLC-#) hydrolyses PI4,5P2 and binds
pTyr 1009 and 1021.  Phosphorylation of Tyr 857 results in full kinase activity of
the PDGFR".   (Adapted from Claesson-Welsh, 1994a)
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become the focus of the next two sections:  the Ras/mitogen activated protein kinase (MAPK) 
pathway (section 1.2.1.1) and the PI3K /Akt pathway (section 1.2.1.2) (Fig. 1.4). 
 
1.2.1 PDGFR signalling pathways 
1.2.1.1 Ras/MAPK pathway 
One of the signalling cascades stimulated by PDGFR activation is the Ras/MAPK 
pathway (McKay and Morrison, 2007).  The Ras/MAPK pathway and in particular the 
phosphorylated MAPK protein is important to the contents of this thesis because it is a 
measurement of signalling output from the PDGFR.  Key proteins within this pathway are 
highlighted in Fig. 1.4.  Upon activation and autophosphorylation of the PDGFR the SHC 
adaptor protein is recruited to the plasma membrane and binds the receptor via its pTyr binding 
domain.  The PDGFR phosphorylates SHC on Tyr 317 (Heldin et al., 1998).  Grb2 contains a 
SH2 domain capable of binding SHC at this phosphorylated tyrosine residue.  Grb2 
constitutively interacts with Son of Sevenless (Sos) and recruits this guanine nucleotide 
exchange factor (GEF) to the plasma membrane.  Sos is brought into the same vicinity as the 
G-protein Ras.  Interaction with Ras bound to guanosine diphosphate (GDP) activates the GEF 
activity of Sos (Margarit et al., 2003); (Freedman et al., 2006; Sondermann et al., 2004) 
causing Ras to exchange the bound GDP for guanosine triphosphate (GTP) to become active.  
RasGTP recruits and activates the serine (Ser)/threonine (Thr) protein kinase activity of Raf 
(Avruch et al., 2001).  Raf phosphorylates MAPK/Erk kinase (MEK) on Ser 218 and Ser 222 
(Zheng and Guan, 1994) thereby activating its dual Tyr and Ser/Thr protein kinase activity.  
MEK in turn phosphorylates MAPK on Thr 183 and Tyr 185 (Payne et al., 1991).  Activated 
MAPK is then able to phosphorylate cytoplasmic and nuclear targets responsible for initiating 
cellular proliferation (McKay and Morrison, 2007).   
 
1.2.1.2 PI3K/Akt pathway 
 The PI3K/Akt pathway is a signal transduction pathway that contributes to several  
Fig. 1.4. PDGFR Signalling Pathways.  The PDGFR is activated and
autophosphorylates specific tyrosine residues which become binding sites for effector
molecules.  PI3K is activated and converts PI4,5P2 into PI3,4,5P3. This leads to the
activation of Akt. Akt contributes to cellular survival in several ways including: 1)
leading to the phosphorylation of p70 S6 kinase (S6K) resulting in the synthesis of
prosurvival proteins and; 2) phosphorylating BAD causing the release the prosurvival
protein Bcl-xL thereby promoting cellular survival by inhibiting apoptotic signals from
Bax.. PTEN dephosphorylates PI3,4,5P3 back into PI4,5P2 resulting in the inactivation
of the Akt pathway. The Ras/MAPK pathway is activated when Grb2 and Sos are
recruited to the plasma membrane by SHC.  Sos is brought into the same vicinity as the
Ras and this interaction activates the GEF activity of Sos causing Ras to exchange the
bound GDP for GTP to become active.  RasGTP recruits and activates Raf.  Raf
phosphorylates and activates MEK.  MEK in turn phosphorylates MAPK. Activated
MAPK is then able to phosphorylate cytoplasmic and nuclear targets responsible for
initiating cellular proliferation.
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cellular functions ultimately resulting in cellular survival (Song et al., 2005); (Manning and 
Cantley, 2007).  Key proteins within this pathway are highlighted in Fig. 1.4.  This pathway is 
stimulated by the activation of the PDGFR.  The PI3K protein (discussed in section 1.2.1.2.1) is 
able to bind to two pTyr residues on the PDGFR via its two SH2 domains.  PI3K converts 
PI4,5P2 to PI3,4,5P3.  Akt is a serine/threonine protein kinase and is recruited to PI3,4,5P3 at the 
plasma membrane via its pleckstrin homology (PH) domain (Andjelkovic et al., 1997).  Akt is 
activated by phosphorylation of two key residues: Thr 308 and Ser 473.  Akt is phosphorylated 
on Thr 308 by phosphoinositide-dependent kinase-1 (Anderson et al., 1998).  The protein 
responsible for Ser 473 phosphorylation has not yet been identified.  After activation, Akt 
contributes to cellular survival in several ways including: 1) the phosphorylation of p70 S6 
kinase (S6K) resulting in the synthesis of prosurvival proteins and; 2) directly phosphorylating 
Ser 136 and inhibiting the proapoptotic protein BAD (Datta et al., 2000).  Phosphorylated BAD 
binds 14-3-3 releasing the pro-survival protein Bcl-xL to bind Bax, which blocks the apoptotic 
function of Bax.  The net result is the promotion of cellular survival by inhibiting apoptotic 
signals.  The phosphatase and tensin homology (PTEN) phosphatase regulates the PI3K/Akt 
pathway by dephosphorylating PI3,4,5P3 back into PI4,5P2 resulting in the inactivation of the 
downstream Akt pathway. 
 The PI3K/Akt pathway and in particular the phosphorylated Akt protein is important to 
the contents of this thesis because it is representative of signalling output from the PDGFR.  
The main focus of this thesis is, however, to better understand how PI3K and PI3K 
protein:protein interactions dictate cellular outcomes within cells.  To do this, a closer look at 
the PI3K protein and function is needed (Section 1.2.1.2.1). 
 
1.2.1.2.1 PI3K 
PI3Ks are grouped into three classes (I-III) that are differentiated by their substrate 
preference and sequence homology (Engelman et al., 2006).   The class I PI3Ks are further 
divided into two subfamilies known as A and B.  Class IA PI3K are activated by growth factors 
and RTKs and the Class IB are activated by G-protein-coupled receptors (Katso et al., 2001).  
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For the purpose of this thesis, only Class IA PI3K will be discussed. Class IA PI3K are 
heterodimers and have a p85 regulatory subunit and a p110 catalytic subunit. The p110 
catalytic subunit is a serine and lipid kinase that has a number of different isoforms: !, ", $. 
Class IA PI3K phosphorylate the D3 position of the inositol ring of phosphatidylinositols 
(Carpenter and Cantley, 1996). The p85 protein is responsible for regulating p110 lipid kinase 
activity and in relocalizing p110 to the plasma membrane (Carpenter and Cantley, 1996).    
There have been five isoforms of the p85 regulatory subunit identified: p85!, p85", 
p55!, p50!, and p55
PIK
 (Harpur et al., 1999).  The p85! and p85" regulatory subunits are 
composed of five domains (Harpur et al., 1999).  They have an N-terminal SH3 domain, a BCR 
homology (BH) domain flanked by two proline rich regions, two SH2 domains, and a p110 
binding site between the two SH2 domains (Fig. 1.5).  The p85!, p55!, and p50! isoforms are 
encoded by the same gene.  The p55! and p50! isoforms are splice variants of p85! and lack 
the N-terminal SH3, BH and the first proline rich regions (Fig. 1.5).  The main difference 
between p55! and p50! is an addition of an amino-terminal extension of 34 aa and six aa, 
respectively, to the sequence common with p85!.  The p85" and p55
PIK 
are analogous to the 
p85! and p55 isoforms, respectively, but are encoded by two different genes.  The p85! 
isoform has been shown to possess intrinsic signalling functions (Harpur et al., 1999).  For the 
remainder of this thesis, the p85! isoform will be referred to as p85 and a more detailed 
analysis of its regulatory functions will be discussed. 
The p85 protein is responsible for regulating p110 lipid kinase activity and in 
relocalizing p110 to the plasma membrane (Fig. 1.6) (Carpenter and Cantley, 1996).  In resting 
cells, p85 is complexed with p110 in the cytosol and inhibits its lipid kinase activity (Yu et al., 
1998).  Upon PDGFR activation, the p85:p110 complex is recruited to the plasma membrane 
by the binding of p85 SH2 domains to pTyr 740 and 751 of the PDGFR (Claesson-Welsh, 
1994a).   The p110 lipid kinase activity inhibition is relieved and the p85 subunit brings the 
p110 subunit in close proximity to its lipid substrates.  The p110 subunit is able to produce the 
second messenger PI3,4,5P3 (Carpenter and Cantley, 1996).  This action is responsible for 
activating downstream signalling cascades (Section 1.2.1.2.)   
 
p85! and p85"
Binds pTyr sites on:
e.g. PDGFR & EGFR
Binds Pro-rich proteins
e.g. dynamin
p110 binding
Binds SH3 of
Src-family
GAP
SH3 p110BBH N-SH2 C-SH2Pro Pro
p55! and p55"PIK
p50!
p110BN-SH2 C-SH2ProPro
34 aa
p110BN-SH2 C-SH2ProPro
6 aa
Fig. 1.5.  Isoforms of the p85 regulatory subunit of PI3K. The p85! and p85"
regulatory subunit are composed of an N-terminal SH3 domain, a BH domain
flanked by two proline rich regions, two SH2 domains, and a p110 binding site
between the two SH2 domains. The p55! and p50! isoforms lack the SH3, the BH
and the first proline rich regions but contain an amino-terminal extension of 34 aa
and six aa respectively.  The p85" and p55"PIK are analogous to the p85! and p55!
isoform.
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ACTIVATION
Fig. 1.6.  The p85 subunit of PI3K is responsible for regulating p110 activity. In
resting cells, p85 is complexed with p110 in the cytosol and inhibits its lipid kinase
activity.  Upon PDGFR activation, the p85:p110 complex is recruited to the plasma
membrane by the binding of p85 to the PDGFR. The lipid kinase activity inhibition is
relieved and p110 is able to produce the second messenger PI3,4,5P3. The p85
subunit brings the p110 subunit in close proximity to its lipid substrates.
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1.3 Endocytosis 
The plasma membrane of a cell is a dynamic structure which functions to separate the 
intracellular cytoplasm from the extracellular matrix (Conner and Schmid, 2003).  It 
coordinates the entry and exit of small and large molecules.  Larger molecules known as 
macromolecules must be carried into the cell by the “pinching off” of the plasma membrane 
into vesicles, a process known as endocytosis.  Endocytosis consists of phagocytosis, eating of 
particles, or pinocytosis, drinking of particles, (Conner and Schmid, 2003).  Phagocytosis 
requires the use of specialized cells such as macrophages.  Pinocytosis, on the other hand, is the 
uptake of fluids or solutes through one of four different mechanisms: macropinocytosis, 
clathrin-mediated uptake, caveolae-mediated uptake, or clathrin/caveolae-independent uptake 
(Fig. 1.7).  All mechanisms of endocytosis differ with regards to the size of vesicle, the nature 
of the cargo (ligands, receptors, lipids) and the mechanism of vesicle formation (Conner and 
Schmid, 2003).  Of particular interest to this thesis is the process of clathrin-mediated 
endocytosis which controls the levels of surface receptors and mediates the downregulation of 
activated signalling receptors. 
  
1.3.1 Receptor-mediated endocytosis 
Clathrin-mediated endocytosis is also known as receptor-mediated endocytosis and is 
initiated/facilitated by ligands binding to receptors (Fig. 1.8) (Conner and Schmid, 2003).  
Vesicles containing activated receptors bound to ligands are encapsulated by a polygonal 
clathrin coat.  Clathrin is a three-legged (triskelion) structure formed by three clathrin heavy 
chains, each with a tightly associated clathrin light chain (Brodsky et al., 2001; Kirchhausen, 
2000).  For vesicle formation, clathrin assembles at the plasma membrane into polygonal cages.  
Clathrin assembly is mediated by assembly proteins, specifically EGFR pathway substrate 
clone 15 (Eps15), epsin, and adapter protein 2 (AP2) (Brodsky et al., 2001; Urbe, 2005). 
 AP2 consists of two large structurally related ! and "2-adaptins, a medium subunit 
known as %2, and a smaller subunit known as &2.  The AP2 has a barrel shaped core where %2 
and &2 are surrounded by both the ! and "2-adaptins.  There are two protruding appendages  
Phagocytosis Pinocytosis
A B C D
Fig. 1.7.  Types of endocytosis: Phagocytosis and Pinocytosis.  Phagocytois is the
engulfing of larger particles by specialized cells.  Pinocytosis is the uptake of fluids or
solutes through one of four different mechanisms: A) macropinocytosis, B) clathrin-
mediated uptake, C) caveolae-mediated uptake, or D) clathrin/caveolae-independent
uptake.
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Fig. 1.8.   PDGFRs are endocytosed into clathrin-coated vesicles.  Clathrin
triskelions assemble into a polygonal lattice around endocytosing PDGFR and plasma
membrane forming a coated pit.  AP2 is recruited to the plasma membrane to mediate
clathrin assembly.  Dynamin forms a ring around the top of the endocytosing vesicle
and mediates membrane scission to release the clathrin-coated vesicle into the cytosol.
(Adapted from Conner and Schmid, 2003)
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found at the carboxy-terminal of the ! and "2-adaptins (Collins et al., 2002).  The !-adaptin 
subunit targets AP2 to the plasma membrane and specifies the site of clathrin assembly, 
whereas the "2-adaptin subunit triggers clathrin assembly (Conner and Schmid, 2003).   The %2 
and the smaller &2 bind tyrosine-based internalization motifs on the activated receptors and 
help to stabilize the core unit respectively (Conner and Schmid, 2003).  AP2 directs clathrin 
assembly into curved lattices and couples clathrin coated vesicles to cargo recruitment 
(Brodsky et al., 2001). 
 At the late stages of clathrin-coated vesicle formation, receptors and their bound ligand 
get concentrated into coated pits which are invaginated plasma membrane that are pinched off 
to form vesicles (Fig. 1.8).  Dynamin self assembles into a collar at the necks of deeply 
invaginated coated pits (Conner and Schmid, 2003).  Dynamin is a large modular GTPase with 
a PH domain that binds PI3P, a GTPase effector domain (GED), and proline/arginine rich 
domains which interact with other endocytosis components.  Dynamin has its own GAP 
activity within the GED which is required for self assembly into helical rings and stacks.  The 
exact mechanism as to how dynamin pinches off vesicles is unknown, but it is known that 
dynamin must undergo GTP hydrolysis driven conformational changes for its activity (Song 
and Schmid, 2003). 
Once the receptors are endocytosed, clathrin is shed from the vesicles and the vesicles 
are able to fuse with internal early/sorting endosomes (Fig. 1.9) (De Camilli et al., 1996).  The 
early/sorting endosome is a key component in the endocytosis pathway as the fate of the 
endocytosed receptor is decided here.  At the early/sorting endosomes receptors are targeted to 
a variety of pathways.  These processes are regulated by a family of small monomeric G 
proteins, known as Rab proteins (discussed in Section 1.3.2.1).  After the release of bound 
ligand and dephosphorylation, receptors can be quickly recycled back to the plasma membrane 
for further rounds of activation and signalling.  Upon receptor monoubiquitination and through 
the recognition of bound ubiquitin (Ub) (discussed in Section 1.3.2.2), receptors can be targeted 
to the multi-vesicular body (MVB) within the late endosome (discussed in Section 1.3.2.3) and 
degraded in the lysosome.   
 
Fig. 1.9. Rab GTPases regulate vesicle fusion events during receptor-mediated
endocytosis. Once the receptors are endocytosed, clathrin is shed from the vesicles
and the vesicles are able to fuse with internal early endosomes.  At the early/sorting
endosomes receptors are targeted to a variety of pathways.  These processes are
regulated by a family of small monomeric G proteins, known as Rab proteins. Rab5 is
responsible for regulating the entry of vesicles into the early endosome.  Rab4 is
responsible for regulating the exit to a recycling pathway, portion of which also
involves Rab11, and Rab 7 is responsible for regulating the entry of the vesicles to the
MVB and a degradative pathway. After the release of bound ligand and
dephosphorylation, receptors can be quickly recycled back to the plasma membrane
for further rounds of activation and signalling.  Upon receptor monoubiquitination and
through the recognition of bound ubiquitin receptors can be targeted to the late
endosome within multi-vesicular bodies (MVB) and degraded in the lysosome.
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1.3.1.1 Rab proteins 
Rab proteins are a part of the Ras superfamily of GTPases (Pereira-Leal and Seabra, 
2000).  There are five families which make up this superfamily: Rab, Rho/Rac/Cdc42, Ras, 
Arf, and Ran.  The largest family are the Rab proteins which are essential regulators of vesicle 
transport pathways.  There have been more than 60 Rabs identified, each numbered in order of 
their discovery (Pereira-Leal and Seabra, 2000).  Rab proteins can be ubiquitously expressed or 
tissue specific (Table 1.3) (Stenmark and Olkkonen, 2001). Rab proteins are responsible for 
regulating vesicle fusion events.  Specifically, Rab5 is responsible for regulating the homotypic 
fusion of early/sorting endosomes and trafficking of receptors.  Rab4 is responsible for 
regulating the exit to a recycling pathway.  Rab 11, together with Rab4, is responsible for 
regulating the slow recycling pathway, and Rab 7 is responsible for regulating the exit of 
vesicles to the late endosome and lysosomal degradative pathway (Fig. 1.9) (Armstrong, 2000; 
Bucci et al., 1992; Mills et al., 1999; Mohrmann and van der Sluijs, 1999; Somsel Rodman and 
Wandinger-Ness, 2000; Stenmark et al., 1994; Ullrich et al., 1994).  
Rab proteins are approximately 25 kDa proteins (Tuvim et al., 2001). They are folded 
into six " strands (five parallel, one antiparallel) which are surrounded by five ! helixes. Rab 
proteins contain two switch regions crucial for interaction with guanine nucleotide exchange 
factors (GEF) and GTPase activating proteins (GAP).  Switch I is located in the loop 2 region 
and switch II is located in the loop 4, helix 2 and loop 5 region of the protein (Fig. 1.10) 
(Tuvim et al., 2001).  Elements responsible for guanine nucleotide (GDP or GTP) binding, 
Mg
2+
 binding, and GTP hydrolysis are conserved for all Rab proteins.  The area responsible for 
GTPase activity is located in five loops that connect the ! helixes and " sheets.  There are 
several aa which function to bind the phosphate, the nucleotide, the Mg
2+
 molecule or facilitate 
hydrolysis (Stenmark and Olkkonen, 2001).  All Rab proteins can tightly associate with 
endosomal membranes through a posttranslational modification of two geranylgeranyl (20 
carbon polyisoprenoid) groups on two cysteine residues found in aa motifs (CXXX, CC, CXC, 
CCXX, CCXXX, where X is any aa) near the carboxy-terminal end of the protein (Fig. 1.10; 
some Rabs only contain one cysteine) (Tuvim et al., 2001). Rab proteins are prenylated by the 
enzyme geranylgeranyl transferase (Seabra et al., 1992). 
Table 1.3.  Rab GTPase subcellular location and function
Name Localization Function Expression
Rab 1 Endoplasmic Reticulum,
cis-Golgi
ER-Golgi transport ubiquitous
Rab2 Endoplasmic Reticulum,
cis-Golgi
Golgi-ER retrograde
transport
ubiquitous
Rab3 Synaptic vesicle Regulation of
neurotransmitter release
neurons
Rab4 Early endosome Endocytic recycling ubiquitous
Rab5 Early endosome, clathrin-
coated vesicles, plasma
membrane
Budding, motility, fusion in
endocytosis
ubiquitous
Rab6 Golgi Retrograde golgi traffic ubiquitous
Rab7 Late endosome Late endocytic traffic ubiquitous
Rab8 Trans-golgi network,
plasma membrane
TGN-PM traffic ubiquitous
Rab9 Late endosome LE-TGN traffic ubiquitous
Rab11 Recycling endosome,
Trans-golgi network
Endocytic recycling via RE ubiquitous
Rab27 Melanosomes, granules Movement of lytic granules
and melanosomes towards
PM
Melanocytes,
platelets,
lymphocytes
Adapted from Stenmark and Olkkonen, 2001
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switch 1
switch 2
Fig. 1.10. Sequence alignment between human Rab proteins highlighting specific
regions within RabGTPases which distinguish them from other GTPases in the
Ras superfamily.  Rab protein specific sequence regions RabF and RabSF are
superimposed on the sequence alignment.  RabF regions are conserved between Rab
family members but make Rab proteins distinct from other branches of the Ras
superfamily.  RabSF regions determine specificity of Rab binding partners between
other Rab proteins.   The red shaded boxes show identical sequence alignment and the
red lettering highlights areas of similar sequence.  The secondary structure of Rab4a is
added to the alignment to give an idea as to where these specific regions are located
throughout the Rab proteins (L-loop, S-sheet, H-helix).  (The blue highlighted region
was added to show a deleted region used in the Huber and Scheidig, 2005 paper and is
not important for this thesis) (Reproduced with permission from A.J. Scheidig. (Huber
and Scheidig, 2005))
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Rab proteins contain specific regions that distinguish them from other GTPases within 
the Ras superfamily (Fig. 1.10).   These specific aa regions are known as Rab F1-5 and Rab SF 
regions (Stenmark and Olkkonen, 2001).  The F1-5 regions are conserved in all Rab families 
and in conjunction with the SF regions, they determine specificity of binding partners for each 
individual Rab protein. 
Rab proteins are membrane associated molecular switches that regulate the budding, 
transport and fusion of endosomes.  Rab proteins are regulated spatially and by their nucleotide 
(GDP or GTP) bound state (Stenmark and Olkkonen, 2001).  Rab proteins interchange between 
inactive and active states by exchanging GDP for GTP, respectively.  The nucleotide exchange 
is regulated by GEFs, while GAPs stimulate the hydrolysis of GTP to GDP by the Rab proteins. 
There is a dramatic conformation change seen within the active site of the Rab protein and their 
switch domains upon binding to GDP or GTP (Fig. 1.11) (Stenmark and Olkkonen, 2001).   
Rab proteins are also regulated spatially (Fig. 1.12).  Prior to growth factor stimulation, 
inactive Rab-GDP is bound to a guanine-dissociation inhibitor (GDI) that masks the 
geranylgeranyl groups and allows the Rab protein to localize to the cytosol.  Upon growth 
factor stimulation, the GDI is removed through the action of a GDI-displacement factor (GDF) 
and Rab-GDP is relocalized to an endosomal membrane.  GDP is replaced with GTP through 
the action of a GEF protein.  Rab-GTP is activated and is able to bind to specific effector 
proteins to mediate membrane fusion events.  After membrane fusion, the Rab GTPase activity 
is accelerated by the action of a GAP protein and the bound GTP is hydrolyzed to GDP 
(Stenmark and Olkkonen, 2001).  The Rab protein is inactivated which then allows the GDI 
protein to bind Rab-GDP and localize it to the cytosol. 
Effector proteins of specific Rab proteins are key to Rab function (Stenmark and 
Olkkonen, 2001).  Effector proteins are a heterogeneous group composed of:  coil-coil proteins 
responsible for membrane tethering and docking, enzymes, and cytoskeleton associated 
proteins.  Rab5 is the best characterized Rab protein in regards to function and effector protein 
associations.  Rab5 is responsible for regulating the homotypic fusion of early endosomes and 
in the trafficking of activated receptor complexes into the early/sorting endosome.  Rab5-GTP 
recruits early endosomal antigen 1 (EEA1) protein to the endosome and is required to facilitate  
AFig. 1.11. Rab5a active site and switch regions change conformation when bound
to GDP or GTP.  Crystal structures of Rab5A complexes.  Switch I (purple), switch II
(red) and the catalytic glutamine (Q79, orange) are highlighted.  The nucleotide
structures, Mg2+ (grey spheres) and small water molecules are also shown.  A) Crystal
structure of inactive state Rab5A-GDP complex A)  Note the catalytic glutamine (Q79)
is directed away from the bound GDP as are the switch regions, particularly switch I
(purple). B) Crystal structure of active conformation of Rab5A bound to a GTP
analogue.  Note the repositioning of the catalytic glutamine (Q79) near the gamma
phosphate of the bound nucleotide.  Compared to the GDP-bound structure in (B),
notice the switch regions have moved significantly. From Zhu et al., 2004 and color
highlighted using Cn3Dv4.1.
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Fig. 1.12. Rab5 GTPase cycles regulate the timing of the assembly/disassembly of
multiprotein complexes involved in receptor trafficking. Prior to growth factor
stimulation, inactive Rab5-GDP is bound to a guanine-dissociation inhibitor (GDI)
which masks the geranylgeranyl groups and allows the Rab5 protein to localize to the
cytosol.  Upon growth factor stimulation, the GDI is removed through the action of a
GDI-displacement factor (GDF) and Rab5-GDP is relocalized to an endosomal
membrane where GDP is replaced with GTP through the action of a guanine
nucleotide exchange factor (GEF) protein.  Rab5-GTP is activated and is able to bind
to specific effector proteins such as EEA1 to mediate membrane fusion events.  EEA1
helps to tether the two endosomal membranes by binding to Rab5 and PI3P for
membrane fusion to take place.  After membrane fusion, the Rab5 GTPase activity is
accelerated by the action of a GAP protein and the bound GTP is hydrolyzed to GDP.
The Rab5 protein is inactivated which allows the GDI protein to bind Rab5-GDP and
localize it to the cytosol.
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fusion events (Mills et al., 1998); (Christoforidis et al., 1999a; Rubino et al., 2000; Simonsen et 
al., 1998).  EEA1 interacts with phosphatidylinositol 3`-phosphate (PI3P) lipids on the 
endosomal membrane through its FYVE zinc finger domain.  EEA1 helps tether incoming early 
endosomal vesicles containing newly endocytosed PDGFR to the early/sorting endosome by 
interacting with both Rab5-GTP and PI3P (Fig. 1.13).  Rab5 and EEA1 have not been shown to 
facilitate the actual membrane fusion event but are responsible for tethering the incoming 
vesicle to the proper endosome.  Membrane fusion is likely facilitated by soluble N-
ethylmaleimide-sensitive factor attachment protein (SNAP) receptor SNARE proteins. 
There are two well-characterized Rab5 mutants used to study Rab5 protein interactions 
and functions (Liu and Li, 1998).  They are Rab5-Q79L and Rab5-S34N.  The Rab5-Q79L 
mutant is locked in the active conformation and only interacts with GTP since mutation of this 
catalytically important glutamine (Fig. 1.11) renders it GTPase defective, whereas the Rab5-
S34N mutant is locked in the inactive conformation and only interacts with GDP.  Using these 
mutants in isolation, it is possible to identify Rab5 binding partners and functions by 
understanding how the protein behaves in both the inactive and active conformations.  These 
mutants are used in this thesis to determine how the p85 subunit of PI3K interacts with Rab5. 
 
1.3.1.2 RTK mediated monoubiquitination 
PDGFRs are targeted for lysosomal degradation by the addition of several single 
ubiquitin (Ub) molecules which act as a signal for the receptor to be sorted to the degradative 
pathway (Marmor and Yarden, 2004).  Ub is a 76 amino acid polypeptide and Ub conjugation 
is mediated through a series of enzymatic reactions (Fig. 1.14) (Hershko and Ciechanover, 
1998). These reactions include an ATP-dependent conjugation of Ub to the active site cysteine 
residue of an E1 enzyme and the transfer of Ub to an E2 conjugating enzyme through a thiol-
ester linkage.  Some E2 enzymes can conjugate Ub directly onto the substrate but in most cases 
an E3 Ub ligase enzyme is needed.  E3 Ub ligases mediate substrate recognition.  Several types 
of E3 ligases exist.  There are the “homologous to the E6-AP carboxy terminus” (HECT) 
domain containing E3 ligases (e.g. Nedd4) which conjugate Ub by proceeding through a thiol-  
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Fig. 1.13.  Rab5 and EEA1 are responsible for tethering endocytosing vesicles
to early/sorting endsomes to facilitate highly specific membrane fusion events.
Rab5-GTP recruits EEA1 to the endosome.  EEA1 interacts with PI3P on the
endosomal membrane through its FYVE zinc finger domain.  EEA1 helps tether
incoming vesicles containing newly endocytosed PDGFR to the early endosome by
interacting with both Rab5-GTP and PI3P.  Rab5 and EEA1 have not been shown to
facilitate the actual membrane fusion event but are responsible for tethering the
incoming vesicle to the proper endosome.  Membrane fusion is likely facilitated by
SNARE proteins.
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Fig. 1.14.  Receptor ubiquitination.  A) The ubiquitination reaction consists of three
steps: the E1 enzyme mediates the ATP-dependent activation of the C-terminal glycine
of ubiquitin, which is conjugated to an active site cysteine through a thiol-ester linkage.
Ubiquitin is then transferred to a cysteine in the active site of E2 enzymes. Although
some E2s can ubiquitinate substrates directly, in most cases an E3 ubiquitin ligase is
required. E3 enzymes mediate ubiquitination in a distinct manner: HECT domain-
containing E3s form a thiol-ester linkage with a ubiquitin transferred from the E2,
which is subsequently conjugated to the substrate. RING finger E3s function as
adaptors that bind both E2 enzymes and substrates to coordinate substrate
ubiquitination. Both reactions result in the formation of an isopeptide bond between the
C-terminal glycine of ubiquitin and the $-amino group of a lysine residue within the
substrate. B) Several types of substrate modification by ubiquitin can ensue:
conjugation with one ubiquitin moiety (mono-ubiquitination), conjugation with
multiple ubiquitin monomers (multi-ubiquitination) or the formation of a ubiquitin
chain branched at internal lysines within ubiquitin (poly-ubiquitination).
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ester:Ub intermediate and the “really interesting new gene” (RING) domain containing E3 
ligases (e.g. Cbl) which act as an adaptor E3 ligase which binds to both the substrate and E2 
conjugating enzyme. 
The Ub molecules are conjugated to the substrate via the ' amino group of lysine 
residues. There are three possible outcomes of ubiquitination (Fig. 1.14).  The substrate can be 
mono-ubiquitinated (one Ub molecule at one site on the substrate), multi-ubiquitinated (mono-
ubiquitinated on several sites) or poly-ubiquitinated (several Ub molecules conjugated into a 
chain at one site).  Mono-ubiquitinated or multi-ubiquitinated proteins are targeted to the 
lysosome for degradation, whereas poly-ubiquitinated proteins are targeted to the proteasome 
for degradation.  Monoubiquitination is critical in PDGFR signalling for late endosomal sorting 
and lysosomal degradation of internalized receptors (Marmor and Yarden, 2004). 
The Cbl family of E3 ligases have been shown to facilitate the ubiquitination of the 
PDGFR (Thien and Langdon, 2001); (Tsygankov et al., 2001).  The structure of Cbl proteins 
include a tyrosine kinase binding (TKB) domain, a RING domain, a proline rich region, and a 
Ub-binding Ub associated (UBA) domain.  There are three Cbl family members: c-Cbl, Cbl-b, 
and Cbl-3.  The c-Cbl family member has been shown to specifically regulate PDGFR 
ubiquitination (Miyake et al., 1998).  The c-Cbl E3 ligase binds the PDGFR at pTyr 1021 and 
becomes phosphorylated itself by the activated receptor which stimulates c-Cbl Ub ligase 
activity (Thien and Langdon, 2001; Tsygankov et al., 2001). 
 
1.3.1.3 Late endosomal sorting 
The early/sorting endosome is different from the late endosome.  It is unclear whether 
the early/sorting endosome matures forming the late endosome or if vesicles are pinched off 
from the early/sorting endosome and form or fuse with the late endosome.  The late endosome 
is characterized by a decrease in pH and accumulation of hydrolytic enzymes (Marmor and 
Yarden, 2004).  The late endosome contains lysobisphosphatidic acid within the endosome and 
PI3P at the membrane (Teis and Huber, 2003).  Late endosome also contain MVBs and 
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activated receptors are endocytosed inside the late endosome forming these internal vesicles.  
Receptors continue to actively signal until they are taken into these MVBs (Clague and Urbe, 
2001).  Late endosomes fuse with the lysosome where receptor degradation takes place 
(Marmor and Yarden, 2004).  Sorting receptors into the MVB involves many steps and the 
sequential recruitment of several multi-protein complexes composed of class E vacuolar protein 
sorting (Vps) proteins (Fig. 1.15) (Urbe, 2005).   
Sorting of receptors into the MVB is controlled by several interdependent mechanisms 
such as conjugating receptors with an Ub molecule, recognition and binding to the ubiquinated 
receptor and finally the invagination of the late endosomal membrane to form a MVB (Teis and 
Huber, 2003).  The PDGFR is ubiquitinated in response to ligand binding (Marmor and 
Yarden, 2004).  The conjugation of the PDGFR with an Ub molecule is a signal for sorting into 
the MVB of the late endosome (Urbe, 2005).  Effector molecules help with the sorting by 
binding to Ub through Ub interacting motif (UIM) or UBA domains. 
Once at the early/sorting endosome, the hepatocyte growth factor-regulated tyrosine 
kinase substrate (Hrs) and signal-transducer molecule (STAM) complex interacts with 
ubiquitinated receptors through the UIM of the Hrs protein (Urbe, 2005).  The Hrs/STAM 
complex recruits the receptor to a specialized area of the early/sorting endosome that is covered 
with a flat clathrin coat.  This clathrin coated area is a concentration device used to trap 
ubiquitinated receptors for the formation of a MVB (Urbe, 2005). 
Hrs plays a central role in MVB formation (Fig. 1.15) (Urbe, 2005).  Hrs recruits 
endosomal sorting complex required for transport (ESCRT) I, II and III which are protein 
complexes required for MVB formation. ESCRT proteins are sequentially recruited to and 
activated at the early/sorting endosome.  They constitute the core of the MVB formation 
machinery and act downstream of Hrs/STAM complexes (Katzmann et al., 2002; Raiborg et 
al., 2003; Urbe, 2005).  Hrs recruits ESCRT I (also known as the tumor susceptibility gene 
(tsg101)) through a four aa motif PS[T]AP.  ESCRT I recruits ESCRT II which is transiently 
associated with early/sorting endosomal membranes in an ESCRT I-dependent manner.  
ESCRT II is then able to recruit ESCRT III which facilitates membrane invagination and 
vesicle formation inside the endosome to form the MVBs.  ESCRT III recruits  
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Fig. 1.15.  Late Endosomal Sorting.  Stimulation with ligand induces activation of
PDGFR, autophosphorylation and endocytosis. A) Cbl is recruited to the PDGFR,
phosphorylated and ubiquitinates the PDGFR. Ubiquitinated receptors are sorted into
clathrin-coated pits by a multiprotein complex that includes coat adaptors such as
Epsin and Eps15. B) At the early endosome, PDGFR can be recycled back to the
plasma membrane.  C) Progression through the endocytic pathway is characterized by
the shedding of clathrin, D) a decrease in the internal pH within the vesicles and the
accumulation of hydrolytic enzymes.  PDGFR trafficking from early/sorting to late
endosomes is dependent on its sustained ubiquitination. MVB sorting is regulated
through recognition of ubiquitinated cargo by Hrs/STAM complex, ESCRT I (tsg101)
and other components of ESCRT complexes. Invagination of the limiting membrane of
the MVB forms internal vesicles. This is coupled to receptor de-ubiquitination and
dissociation of the ESCRT complex from endosomes, mediated by the ATPase Vps4.
Fusion of the late endosome with the lysosome results in degradation of the contents of
the internal vesicles.
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the deubiquitinating enzyme Doa4 (Amerik et al., 2000) before vesicle formation so Ub can be 
recycled back to the cytosol for further conjugation reactions. The last step in MVB formation 
is the ATP-dependent dissociation and recycling of the ESCRT proteins by Vps4. 
PDGFR endocytosis contains many steps of activation and regulation.  There are 
numberous proteins and functions which, if compromised, could result in defective PDGFR 
downregulation.  The next section will highlight numerous cellular outcomes when several 
parts of this pathway are interrupted. 
 
1.3.2 Defects in endocytosis and cancer 
Receptor overexpression or receptors containing activating mutations have resulted in 
cancerous phenotypes (Blume-Jensen and Hunter, 2001).  Receptor endocytosis is a process 
which regulates the downregulation of signalling from surface receptors.  There are several 
steps within the endocytic pathway, which, when affected, could result in defective 
downregulation.  It has been shown that mutations involved in MVB sorting signals such as 
mutations of Ub or ubiquitinating enzymes have all been found in human cancers (Jiang and 
Beaudet, 2004).  The loss of Ub conjugation to activated receptors has resulted in increased 
recycling of the receptor back to the cell surface for further rounds of activation and signalling 
(Levkowitz et al., 1998).  Mutated receptors that can no longer bind Cbl, or Cbl mutations 
which knock out its E3 ligase activity have also been shown to result in defective receptor 
downregulation (Bache et al., 2004; Peschard and Park, 2003).  Further down in the MVB 
sorting pathway, the ESCRT protein tsg101 has also been linked to the development of tumors 
(Bache et al., 2004; Katzmann et al., 2002).  As defects in the endocytic pathway can lead to 
defective receptor downregulation, a better understanding of the pathway and the proteins 
involved will allow research to evolve to include this pathway in the repertoire of cancer 
fighting therapies.   
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1.4 RabGAP function of p85  
More recently it is becoming apparent that p85 has regulatory functions beside those 
involving p110.  Our lab specifically has studied the interactions between the p85 subunit and 
A-Raf (Fang et al., 2002; King et al., 2000; Mahon et al., 2005), ankyrin3 (Ignatiuk et al., 
2006), and PTEN (unpublished data).  We have shown that p85:A-Raf regulates PDGFR 
function, that p85:ankyrin3 interactions appear to target activated PDGFRs for lysosomal-
mediated degradation and that the p85:PTEN interaction significantly increases PTEN lipid 
phosphatase activity.  Of particular interest to this thesis is the discovery that p85 has GAP 
activity towards Rab5 and Rab4 (Chamberlain et al., 2004).  It has been shown previously that 
the p85 subunit of PI3K stays associated with the PDGFR during receptor endocytosis 
(discussed in Section 1.3.2) (Kapeller et al., 1993) and can bind directly to Rab5.  As 
previously discussed, Rab5 is a G-protein which localizes to early and sorting endosomes and 
regulates the movement of vesicles containing activated PDGFR from the plasma membrane to 
sorting endosomes (Section 1.3.2.1) (Chamberlain et al., 2004).  Furthermore, studies have 
shown that p85 binding sites on PDGFRs are required for proper receptor down-regulation 
(Joly et al., 1994).  Thus p85 may play a role in helping to regulate the process of receptor 
degradation by interacting both with activated receptors and the Rab proteins that control 
receptor endocytosis and recycling. 
GAP domains downregulate G-proteins by stimulating the intrinsic GTPase activity of 
the G-protein to hydrolyse bound GTP to GDP.  GAP proteins function by stabilizing the 
switch regions of the bound GTPase protein so that the catalytic glutamine residue is positioned 
properly and by supplying a charged arginine residue to the GTPase active site (Clabecq et al., 
2000).  During the hydrolytic reaction, nucleophilic attack of water upon the # phosphate of 
GTP to form GDP + Pi, involves several steps including: deprotonation of the attacking water 
molecule, transition state complex formation, and rearrangement of the enzyme and solvent.  
The addition of Mg
2+
 is required for guanine stabilization (Fig. 1.16) (Sprang, 1997). 
The p85 subunit of PI3K contains a GAP-like BH domain with sequence homology to 
RhoGAP proteins involved in regulating Rho GTPases such as Cdc42 and Rac1.  In earlier 
work, p85 was found to bind both proteins but did not posses GAP activity towards either  
GMP P#
P
"
Mg2+
H20
Gln
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+
-
-
Rab Protein
RabGAP Protein
Fig. 1.16. GAP proteins stimulating the intrinsic GTPase activity of Rab proteins
to hydrolyse bound GTP to GDP.  GAP proteins function by stabilizing the switch
regions of the bound Rab protein so that the catalytic glutamine residue is positioned
properly and by supplying an arginine residue to the GTPase active site.  During the
hydrolytic reaction, nucleophilic attack of water upon the # phosphate of GTP to form
GDP + Pi, involves several steps including: deprotonation of the attacking water
molecule, transition state complex formation, and rearrangement of the enzyme and
solvent.  The addition of Mg2+ is required for guanine stabilization (Adapted from
Scheffzek et al., 1998).
Switch II
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protein (Zheng and Guan, 1994); (Bokoch et al., 1996).  The crystal structure of the p85 BH 
domain revealed a distinct folding pattern capable of binding a G-protein suggesting that p85 
may possess GAP activity towards an unidentified G-protein (Musacchio et al., 1996).  Later 
work, from our laboratory, revealed the p85 protein had GAP activity encoded in its BH 
domain selective for Rab5, Rab4, but not Rab11 (Chamberlain et al., 2004).  It was also found 
to possess GAP activity towards Cdc42 and Rac1 but at higher concentrations of p85 than had 
been previously tested.  The ability of p85 to possess GAP activity towards Rab5 and Rab4 
suggested that p85 may play a central role in coordinating receptor endocytosis and cell 
signalling.  To investigate this hypothesis our lab generated several p85 domain mutants and 
studied their effects on normal receptor endocytosis and cell signaling (discussed in Section 
1.4.1).  The results of these studies, in particular the results from the p85-(BH, p85-R274A and 
the p85-(110 mutants, lead to us to hypothesize a new model of p85 interaction with Rab5 and 
activated receptors known as the ‘hand-off” model (discussed in Section 1.4.2). 
 
1.4.1 p85-R274A, p85-!BH and p85-!110 mutants of p85 
Stable NIH 3T3 cell lines were produced, expressing mutants of p85 that contained 
different p85 domain combinations, to study the effects each mutant had on receptor 
endocytosis and cell signalling.  The proteins were expressed as FLAG-tagged fusion proteins 
for detection.  Cell lines expressing two of these mutants, p85-(BH (deletion of the BH domain 
and flanking proline rich regions) and p85-R274A (point mutation within the BH domain) have 
been characterized (Chamberlain et al., 2004). Both mutants were tested for RabGAP activity.  
As the GAP activity was found to be encoded in the BH domain, it was expected, and 
confirmed, that each mutant would show reduced GAP activity towards Rab5 (Fig. 1.17) 
(Chamberlain et al., 2004).  The GAP activity of the p85-R274A mutant was reduced more so 
than that of the p85-(BH mutant.  Both mutants were then tested for their ability to bind Rab5.  
The p85-wt bound to both Rab5-GTP and Rab5-GDP.  However, the p85-(BH protein bound 
only Rab5-GTP and the p85-R274A protein only bound to Rab5-GDP (Fig. 1.18) (Chamberlain 
et al., 2004).    Although defective for RabGAP activity, each mutant retained the domain 
responsible for  
Fig. 1.17 The BH domain of the p85! encodes Rab5 GAP activity. Rab5 was
loaded with [!32P]GTP, and hydrolysis to [!32P]GDP was assayed for 10 min in the
absence and presence of increasing concentrations of p85 as indicated. A)
Nucleotides were resolved by thin layer chromatography and visualized using a
phosphorimager. B) GAP assay testing the ability of different domains of p85 (10
"M each) to stimulate the GTPase activity of Rab5. C) GAP assay comparing the
ability of wild type (p85-WT) and mutant (p85-R151A and p85-R274A) p85
proteins to accelerate the GTPase activity of Rab5.  Reproduced with permission
from Chamberlain et al. (2004).
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Fig. 1.18. The p85 protein binds directly to Rab5-GTP and Rab5-GDP.  GST and
GST-Rab5 were immobilized on glutathione Sepharose beads and loaded with the
indicated nucleotide. Purified PreScission-cleaved p85 was added and bound p85 was
detected after washing, using an immunoblot analysis with anti-p85 antibodies. A)
GST and GST-Rab5 mutants known to selectively bind GDP (S34N) or GTP (Q79L)
were used in a pull-down assay with wild type p85 protein B) the indicated p85
mutants were tested for their abilities to bind to GST (control), GST-Rab5S34N-GDP,
and GST-Rab5Q79L-GTP as described above. Reproduced with permission from
Chamberlain et al. (2004).
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binding the p110 catalytic subunit for PI3K and was therefore tested to determine if/how PI3K 
subunit associations was affected by the mutants.  Both mutants were tested for their ability to 
bind to p110! and as expected both mutants were able to interact with p110! and stimulate 
PI3K activity to a degree comparable to that of the full length p85 (Fig. 1.19) (Chamberlain et 
al., 2004).  Because each mutant did possess defective RabGAP activity, the two proteins were 
tested for their ability to affect PDGFR downregulation and activation as compared to control 
NIH 3T3 cells and cells expressing p85-wt.  The normal degradation of the PDGFR was slowed 
down by both mutants, with p85-R274A exerting a greater effect (Fig. 1.20) (Chamberlain et 
al., 2004).  PDGFR activation was assessed by tyrosine phosphorylation of the PDGFR and the 
ability of the PDGFR to activate downstream signalling pathways such as the PI3K/Akt and 
Ras/MAPK pathway.  Cells expressing the p85-R274A and p85-(BH proteins showed 
enhanced PDGFR tyrosine phosphorylation (Fig. 1.20).  The cells did, however, show near 
normal activation/phosphorylation of Akt as compared to control cells, but showed an increase 
in MAPK activation/phosphorylation; this was particularily true for p85-R274A expressing 
cells (Fig. 1.21) (Chamberlain et al., 2004).  Lastly, the cells were tested for PDGFR 
associations during growth factor stimulations.  The p85-R274A mutant remained associated 
with the receptor for longer periods of time as compared to p85-wt (Fig. 1.22) (Chamberlain et 
al., 2004).   
Upon further investigation of cells expressing the p85-R274A mutant, our lab has now 
shown that defective Rab GAP activity leads to tumour formation in nude mice (Fig. 1.23) 
(Chamberlain et al., 2008).  These cells possess the hallmarks of transformed cells.  We show 
p85-R274A expressing cells have several characteristics indicative of deregulated growth.  
These cells show a loss of contact inhibition for cell growth and are able to grow independent 
of attachment (Fig. 1.24) (Chamberlain et al., 2008).  Furthermore, the co-expression of a 
dominant negative Rab5-S34N mutant with p85-R274A could block p85-R274A-induced 
transformed properties (Fig. 1.25) (Chamberlain et al., 2008). 
Similar experiments that were used to characterize the p85-(BH and p85-R274A cell 
lines were used to begin characterizing other p85 mutant cell lines (unpublished data).  In 
particular, the p85-(110 mutant, which no longer bound the p110 catalytic subunit of PI3K due  
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Fig. 1.19. The p85 BH domain mutants retain their ability to bind to p110 and
associate with PI3K activity. COS-1 cells were cotransfected with the indicated
FLAG-p85 encoding plasmid together with one encoding Myc-p110, or left
untransfected as a control. A) lysates (20 "g of total protein) from each were
immunoblotted with anti-Myc antibodies, stripped, and reprobed with anti-FLAG
antibodies. B) lysates (200 "g of total protein) were immunoprecipitated (IP) with
anti-FLAG antibodies and immunoblotted with anti-Myc antibodies, stripped and
reprobed with anti-FLAG antibodies. C) anti-FLAG immunoprecipitates were
assayed for associated PI3K activity. Radiolabeled PI3K lipid products were resolved
by thin layer chromatography and visualized using a phosphorimager. As a positive
control, an anti-p85 immunoprecipitate of lysates from untransfected NIH 3T3 cells
was also assayed for associated PI3K activity. Reproduced with permission from
Chamberlain et al. (2004).
39
A
0
1
0
3
0
6
0
1
2
0
2
4
0
B
0
1
0
3
0
6
0
1
2
0
2
4
0
NIH 3T3
FLAG-p85
FLAG-p85-!BH
Time with
PDGF (min.)
Blots: FLAG
FLAG-p85-R274A
Blots: pTyr (upper)
Blots: PDGFR (lower)
Fig. 1.20. Overexpression of FLAG-p85-R274A slows the down-regulation of the
activated PDGFR. Untransfected NIH 3T3 cells, or cells stably expressing wild type
FLAG-p85, FLAG-p85-#BH, or FLAG-p85-R274A, were stimulated with PDGF BB
for the indicated times. Cell lysates (20 "g of protein per lane) were probed in an
immunoblot analysis with the indicated antibodies. Results are typical for at least
three independent experiments. Reproduced with permission from Chamberlain et al.
(2004).
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Fig. 1.21. Overexpression of FLAG-p85-R274A activates the MAPK pathway.
Untransfected NIH 3T3 cells, or cells stably expressing wild type FLAG-p85, FLAG-
p85-#BH, or FLAG-p85-R274A, were stimulated with PDGF BB for the indicated
times. Cell lysates (20 "g of protein per lane) were probed in an immunoblot analysis
with the indicated antibodies. Results are typical for at least three independent
experiments. Reproduced with permission from Chamberlain et al. (2004).
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Fig. 1.22. The p85 BH domain mutants retain their ability to bind to activated
PDGFRs.  NIH 3T3 cells stably expressing the indicated FLAG-p85 proteins were
stimulated for various times with PDGF BB.  Lysates (200 "g) from each cell line were
immunoprecipitated (IP) with anti-PDGFR antibodies and immunoblotted with anti-
FLAG antibodies (for cells expressing FLAG-p85, FLAG-p85  BH, and FLAG-p85-
R274A), or with anti-p85 antibodies (for untransfected NIH 3T3 cells).  Reproduced
with permission from Chamberlain et al. (2004).
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Fig. 1.23.  The p85-R274A-expressing cells form tumors in nude mice. NIH 3T3
or p85-R274A cells (2.5 x 106) were injected subcutaneously into the right flank of
each of four nude mice. A) the average tumor volume was plotted over time for mice
injected with p85-R274A-expressing cells (squares) or control NIH 3T3 cells
(triangles). B) a mouse injected with p85-R274A-expressing cells with the tumor
indicated by the arrow is shown. C) hematoxylin-eosin staining shows the
architecture of a typical tumor. The top panel shows the tumor infiltrating the muscle
(x10 magnification). The middle panel shows the fascicles and spindle architecture of
the tumor (x100). The bottom panel shows a typical high-powered (x400) field of
view. Reproduced with permission from Chamberlain et al. (2008).
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Fig. 1.24. p85-R274A-expressing cells lack contact inhibition and anchorage
dependence for growth, indicative of transformed cells. A) the indicated cell
lines were plated (2.5 x 105 cells/10-cm plate), and after 14 days of growth, the cells
were stained with Giemsa and viewed for focus formation. A typical result from one
of three independent experiments is shown. B) cells (5 x 104) were plated in soft
agar and grown for 20 days. A typical field of view is shown. The mean ± S.D. of
the number of colonies formed per 5 x 104 cells plated from three independent
experiments is shown. **, p < 0.001 compared with the NIH 3T3 control.
Reproduced with permission from Chamberlain et al. (2008).
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Fig. 1.25.  Coexpression of Rab5-S34N reverts the transformed properties of p85-
R274A-expressing cells. A) flattened morphology of cells expressing both Rab5-
S34N and p85-R274A. B) reduced focus formation upon coexpression of Rab5-S34N
with p85-R274A. Experiments were carried out as for Fig. 1.24, and a typical result
from one of three independent experiments is shown. C) reduced anchorage-
independent growth in soft agar of cells coexpressing Rab5-S34N and p85-R274A.
Experiments were as described for Fig. 1.24, where the mean ± S.D. from three
independent experiments was determined. *, p < 0.01 compared with p85-R274A cells.
Reproduced with permission from Chamberlain et al. (2008).
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to a well characterized small deletion (aa 478-513) in the p110 binding domain (Klippel et al., 
1993), was studied.  As expected, this mutant did not bind to p110! (Fig. 1.26).  Unexpectedly, 
p85-(110 overexpression had little or no effect on PDGFR-associated PI3K activity (Fig. 
1.27).  The p85-(110 protein was also found to spend longer periods of time associated with 
the activated receptor during time course experiments as compared to control p85 protein, 
suggesting that it was not released from the receptor (Fig. 1.27).  As noted earlier, this was also 
observed for the p85-R274A protein. 
These observations led us to investigate how p85 interacted with Rab5 during 
endocytosis. The results shown by the mutant p85-R274A, p85-(BH and p85-(110 proteins 
influenced a proposed model of interaction between p85 and Rab5 during receptor endocytosis 
known as the “hand-off” model (Section 1.4.2).   
 
1.4.2 “Hand-off” model to describe the interaction between p85 and Rab5 during PDGFR 
endocytosis 
How p85 may interact with activated receptors, p110", and Rab5 can be explained 
using the sequential “hand-off” model (Fig. 1.28).  Previous studies have shown Rab5-GTP 
associates with p110" but not p110! and that the p110" protein is known to specifically bind to 
Rab5-GTP and not to Rab5-GDP (Christoforidis et al., 1999b).  These same studies showed 
that p85 was able to interact and bind to Rab5 only when associated with p110" (Christoforidis 
et al., 1999b).  As stated previously, it is now known p85 can interact with Rab5 directly 
(Chamberlain et al., 2004).  This model suggests p85 assists in Rab5 relocalization to the 
endosomal membrane, early in receptor endocytosis, perhaps acting as a GDF. Prior to growth 
factor stimulation, inactive Rab5-GDP bound to a GDI protein is localized to the cytosol.  
Upon growth factor stimulation, Rab5-GDP is relocalized to the endosomal membrane.  Since 
p85 can bind directly to Rab5-GDP and is known to remain bound to the tyrosine 
phosphorylated PDGFR during endocytosis, this interaction may assist in Rab5 relocalization 
and ensure that Rab5 is targeted to the correct endosomal compartment (Kapeller et al., 1993).  
Fig. 1.26. Mutant FLAG-p85 proteins behave as expected with regard to their
ability to bind to the catalytic subunit of PI3 kinase, p110.  COS-1 cells were
cotransfected with each of the FLAG-p85 plasmids together with a plasmid encoding
N-terminal triple Myc (EQKLISEEDL)-tagged p110.  Three days after transfection,
cells were lysed and immunoprecipitated with anti-FLAG antibodies and tested for
associated Myc-p110 protein with a Myc immunoblot (upper) and a control FLAG
immunoblot (lower). The p85-BH results are not important for this thesis.
(Experiments performed by John Hanson and Dean Chamberlain)
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Fig. 1.27.  The p85-!110 protein binds to the activated PDGFR for longer periods
of time as compared to p85-wt but does not interfere with PDGFR-associated PI3
kinase activity.  NIH 3T3 cells were stimulated with PDGF. A) Anti-PDGFR
immunoprecipitations followed by anti-FLAG immunoblots were tested for PDGFR
associations.  B) Anti-PDGFR immunoprecipitations were tested for PI3 kinase
activity. (Experiments performed by John Hanson and Dean Chamberlain)
48
Fig. 1.28. Sequential “hand-off” model to describe p85 interactions with activated
receptors, p110#, and Rab5.   A) Prior to growth factor stimulation, inactive Rab5-
GDP bound to a GDI protein is localized to the cytosol.  Upon growth factor
stimulation, Rab5-GDP is relocalized to the endosomal membrane.  Since p85 can bind
directly to Rab5-GDP and is known to remain bound to the tyrosine phosphorylated
PDGFR during endocytosis, this interaction may assist in Rab5 relocalization and
ensure that Rab5 is targeted to the correct endosomal compartment by acting as a GDF.
B) Rab5 exchanges its GDP for GTP through the action of a GEF.  Rab-GTP is the
active conformation important for vesicle fusion events in receptor trafficking.  C) The
p85 protein directly binds Rab5-GTP and p110!.  The p110! protein is known to
specifically bind to Rab5-GTP and not to Rab5-GDP (Christoforidis et al., 1999).  We
hypothesize that both p85 and p110! bind Rab5-GTP and the formation of this trimeric
complex allows the release of p85 from the receptor with a corresponding increase in
p85 RabGAP activity.  D) The GAP activity of p85 could then stimulate the hydrolysis
of GTP to GDP by Rab5 whereby Rab5-GDP would leave the membrane and bind GDI
to return to the cytosol.
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Thus, PDGFR-associated p85 may act as a GDF.  Rab5 exchanges its GDP for GTP through 
the action of a GEF.  Rab-GTP is the active conformation important for vesicle tethering events 
resulting in receptor trafficking.  The p85 protein directly binds Rab5-GTP and p110".  We 
hypothesize that both p85 and p110" bind Rab5-GTP and the formation of this trimeric 
complex allows the release of p85 from the receptor with a corresponding increase in p85 Rab 
GAP activity.  The GAP activity of p85 could then stimulate the hydrolysis of GTP to GDP by 
Rab5 whereby Rab5-GDP would leave the membrane and bind GDI to return to the cytosol. 
The results shown by the mutant p85-(BH, p85-R274A, and p85-(110 proteins 
influenced the proposed model.  The p85-wt protein can bind to Rab5 in both GDP and GTP 
conformations.  We hypothesize that the ability of the p85 protein to bind to Rab5-GDP may 
help to localize the Rab5 protein to membranes containing activated receptors undergoing 
endocytosis.  The p85-(BH only binds Rab5-GTP; therefore cells expressing this mutant will 
lose p85-dependent Rab5 membrane localization possibly resulting in this targeting process 
being less efficient.  After nucleotide exchange the p85-(BH can bind to Rab5-GTP and p110 
resulting in release from the receptor.  The p85-(BH cannot, however, effectively accelerate 
Rab5 GTPase activity since its BH domain is missing, thus Rab5 remains on the membrane in 
its active GTP-bound form promoting vesicle fusion events.  On the other hand, p85-R274A 
binds only Rab5-GDP and would still be able to help localize Rab5 to those specific 
membranes.  The p85-R274A mutant would not be able to bind to Rab5-GTP after Rab5 
nucleotide exchange or stimulate GTP hydrolysis.  The p85-R274A mutant would not be able 
to form the trimeric complex between p110" and Rab5 and would not be released from the 
receptor.  The p85-R274A mutant would remain bound to the PDGFR.  Rab5-GTP would stay 
associated with the membrane for longer periods of time, as compared to the p85-(BH 
expressing cells, promoting vesicle fusion events.  The p85-(110:Rab5 binding specificities 
and GAP activity are unknown.  However, this mutant cannot bind p110 and remains 
associated with the activated PDGFR during time-course experiments.  As defined by our 
model, cells expressing this mutant would have the same phenotype as those expressing p85-
R274A.  The p85-(110 still contains its BH domain suggesting it would possess GAP activity, 
as this activity is independent of PI3K activity.  However, without the ability of p85-(110 to 
bind p110, the p85, p110", and Rab5 would not be released from the PDGFR and the GTPase 
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activity would not be fully increased.  The p85-(110 would remain bound to the PDGFR.  This 
would again suggest Rab5 would remain associated with the membrane in its active state 
promoting vesicle fusion.  As p85 was found to have GAP activity towards both Rab5 and 
Rab4, the model would suggest an increase in membrane fusion events for both the endocytic 
and recycling pathways.  The net effect would be decreased receptor degradation due to fewer 
opportunities for the receptor to be targeted to the degradative pathway.  
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2.0 RATIONALE AND OBJECTIVES 
2.1 Rationale 
The main focus of our laboratory is to better understand the function of the Class IA 
PI3K, p85:p110.  Our studies focus on understanding how the subunits of PI3K, mainly the p85 
subunit, interact with effector molecules and how these interactions influence cell signalling.  
Previously our lab has studied the interactions between the p85 subunit with A-Raf (Fang et al., 
2002; King et al., 2000; Mahon et al., 2005) and Ankyrin 3 (Ignatiuk et al., 2006).  Currently 
our lab has begun to characterize the interactions between p85 and Rab5 (Chamberlain et al., 
2004; Chamberlain et al., 2008).  The realization that p85 could be involved in other activities 
beside p110 regulation led the way to investigate the functions of different domains of p85 by 
creating several p85 mutants and stably expressing them in NIH 3T3 cells.  Cells were then 
studied to determine the effects the p85 mutants had on PDGFR signalling and the cellular 
consequences brought about due to these effects (Section 1.4.1)  The characterizations of the 
mutant p85-R274A, p85-(BH and p85-(110 proteins influenced a proposed model of the 
interaction between p85 and Rab5 during PDGFR endocytosis known as the “hand-off” model 
(Section 1.4.2).   
 
2.2 Objectives 
The main goal of this project was to characterize the interactions between the p85 
protein with activated PDGFR and Rab5.  The experimental objectives were as follows:   
1. To determine the p85 domains involved in binding Rab5-GDP and Rab5-GTP. 
2. To determine the mechanism(s) of defective PDGFR degradation in cells expressing the 
p85-R274A mutant. 
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3.0 MATERIALS AND METHODS 
3.1 Materials 
3.1.1 Reagents and Supplies 
 All of the chemicals and enzymes used were of analytical grade or higher and were 
purchased from VWR, BDH or Sigma unless otherwise stated.  Glutathione Sepharose beads 
(Amersham Pharmacia Biotech), Protein G Agarose (Sigma), and Protein A Sepharose beads 
(Sigma) were prepared according to the manufacturer’s instructions and were stored at 4°C, 
stable for several months.  Glutathione Sepharose beads were used for the purification of GST 
fusion proteins and pull-down experiments, while Protein G Agarose and Protein A Sepharose 
beads were used for immunoprecipitation (IP) experiments.  Premade TrueBlot anti-Rabbit Ig 
IP beads (eBioscience) were used according to the manufacturer’s instructions for IP 
experiments and stored at 4°C. 
 Several primary antibodies were used for the immunoprecipitation, immunofluorscence 
and immunoblotting experiments.  The antibodies were obtained from a variety of different 
sources and are described in Table 3.1.  Anti-PDGFR 958 (Santa Cruz Biotechnology, sc-432) 
and anti-rabbit IgG agarose conjugate (Santa Cruz Biotechnology, sc-2345) were used in the 
immunoprecipitation experiments. Anti-Rab5 (Abcam, #ab50523), anti-Rab4 (BD 
Transduction Laboratories, #610888), anti-phosphoPDGFR (pY857) (Santa Cruz 
Biotechnology, sc-12907-R) and secondary antibodies Alexa 488 (green) and Alexa 594 (red) 
(Molecular Probes) were used in the immunofluorescence experiments.  The following primary 
antibodies were used for immunoblotting:  anti-ubiquitin P4D1 (Santa Cruz Biotechnology, sc-
8017), anti-pTyr (pY20) (Santa Cruz Biotechnology, sc-508), anti-PDGFR" 2B3 (New 
England Biolaboratory, 3175), anti-phosphoPDGFR (pY1021) (Santa Cruz Biotechnology, sc-
12909-R), anti-Cbl 7G10 (Millipore, 05-440), anti-FLAG M2 (Sigma, F3165), anti-p85-N-SH3 
(Upstate Biotechnology Institute, 05-217), affinity purified anti-p85-BH (specific for amino 
acids: 78-332, (Chamberlain et al., 2004)) and affinity purified anti-p85-(N+C)SH2 (specific 
for amino acids:  312-722, Fang et al., 2002; (King et al., 2000).  The secondary antibodies 
used were horseradish peroxidase-coupled anti-mouse IgG (Santa Cruz Biotechnology, sc-  
Antibody
Specificity
Company, Catalog # Species Concentration
used
Applicatio
n
Figure
Anti-PDGFR
(958)
Santa Cruz Biotechnology,
 sc-432
rabbit 5 !g/mL
1 !g/mL
0.5 !g/mL
IP
WB
 IF
4.8, 4.9
 4.10
4.11, 4.12
Anti-PDGFR
(2B3)
New England Biolabs,
3175
mouse 1 !g/mL WB 4.8
Anti-Rab5 Abcam, #ab50523 mouse 1 !g/mL IF 4.11, 4.13
Anti-Rab4 BD Transduction
Laboratories, #610888
mouse 3 !g/mL IF 4.12, 4.14
Anti-phospho
PDGFR (pY857)
Santa Cruz Biotechnology,
sc-12907-R
rabbit 0.5 !g/mL IF 4.13, 4.14
Anti-phospho
PDGFR
(pY1021)
Santa Cruz Biotechnology,
sc-12909-R
rabbit 1 !g/mL WB 4.8
Anti-pTyr
(pY20)
Santa Cruz Biotechnology,
sc-508
mouse 1 !g/mL WB 4.8
Anti-ubiquitin
(P4D1)
Santa Cruz Biotechnology,
sc-8017
mouse 1 !g/mL WB 4.8
Anti-Cbl (7G10) Millipore, 05-440 mouse 1 !g/mL WB 4.8, 4.9
Anti-FLAG
(M2)
Sigma, F3165 mouse 5 !g/mL WB 4.8
Anti-p85 (N-
SH3)
Upstate Biotechnology
Institute,
 05-217
mouse 2 !g/mL WB 4.2, 4.4,
4.8
Anti-p85 (BH) Anderson, affinity purified
( to amino acids:  78-332)
rabbit 1 !g/mL WB 4.2, 4.4,
4.5,4.7
Anti-p85
((N+C)SH2)
Anderson, affinity purified
( to amino acids:  312-722)
rabbit 1 !g/mL WB 4.2, 4.4
Table 3.1. Primary antibodies used for immunoprecipitation (IP), Western
Blot (WB), and immunofluorescence (IF)
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2005) and horseradish peroxidase-coupled anti-rabbit IgG (Santa Cruz Biotechnology, sc-
2004). 
 
3.1.2 Plasmids and Vectors 
The pGEX6P1 vector (Amersham Pharmacia Biotech) is designed for isopropyl "-D-
thiogalactopyranoside (IPTG)-induced protein production in bacteria.  High levels of 
glutathione S-transferase (GST) fusion proteins are produced after transformation with this 
vector.  This vector contains an ampicillin resistance gene and encodes a PreScission protease 
cleavage site (LEVLFQ*GP, the asterisk indicates the cleavage site).  The protease cleavage 
site, situated between GST and the fusion protein, is important to allow removal of the GST 
portion during protein purification.  The pGEX6P1 vector was used to express the bovine p85-
wild type (wt, aa 1-724) and p85 mutant proteins: p85-R274A (aa 1-724), p85-SH3 (aa 1-83), 
p85-SH3-Pro-BH-Pro (aa 1-332), p85-Pro-BH-Pro (aa 77-322), p85-Pro-BH (aa 79-301), p85-
BH-Pro (aa 110-332), p85-BH (aa 110-301), p85-(N+C)SH2 (aa 314-724), p85-N-SH2 (aa 
314-446), p85-C-SH2 (aa 614-724), p85-p110B (p110 binding domain, aa 431-623), p85-(BH 
(aa 1-83, 314-724), p85-(SH3 (aa 78-724), p85-(110 (aa 1-477, 514-724).  Plasmids 
containing the dog Rab5 mutant sequences (Rab5-Q79L and Rab5-S34N, aa 2-215) were 
generously provided by Dr. M. Zerial from the Max Planck Institute of Molecular Cell Biology 
and Genetics, Dresden, Germany. 
The pFLAG3 vector was a modification of the HA3 vector and was described 
previously (Chamberlain et al., 2004).  This vector is designed to make fusion proteins 
containing three copies of the FLAG epitope (DYKDDDDK) fused to the N-terminus of the 
protein.  This vector is a mammalian expression plasmid and contains both ampicillin and 
Geneticin resistance genes.  The pFLAG3 vector was used to express the bovine p85 wild type 
and p85 mutant proteins in eukaryotic stable cell lines. 
 
3.1.3 Bacterial Strains 
The pGEX6P1 plasmids were expressed in both Escherichia coli (E. coli) BL21 cells 
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[F
-
 ompT hsdSB (r B
-
mB
-
) gal dcm] (Novagen) and E. coli TOP10 cells [F
-
 mcrA (mrr
-
hsdRMS
-
mcrBC) 80lacZM15 lacX74 recA1 ara139 (ara-leu)7697 galU galK rpsL (StrR) endA1 nupG] 
(Invitrogen).  The pGEX6P1 plasmids were expressed in the E. coli BL21 cells for protein 
purification experiments as these cells are protease deficient, thereby decreasing protein 
degradation.  The pGEX6P1 plasmids were expressed in the E. coli TOP10 cells for the 
production of plasmid DNA.  Both E. coli strains were grown in Luria-Bertani Broth (LB, 
Sigma) containing 1%(w/v) bacto-tryptone, 0.5%(w/v) bacto-yeast extract and 1%(w/v) sodium 
chloride (NaCl) pH 7.0, per litre and 100 %g/mL ampicillin (LBA, Sigma). 
 
3.1.4 Mammalian Cell lines 
NIH 3T3 mouse fibroblast cells were obtained from American Type Culture Collection.  
NIH 3T3 cells were maintained in Dulbecco’s Modified Eagle Medium (DMEM, Gibco) 
supplemented with 10% fetal bovine serum (FBS, Hyclone) 100 units/ml penicillin G and 100 
%g/ml streptomycin (P/S, Gibco) and grown at 37°C with 5% CO2.  NIH 3T3 cells stably 
transfected with pFLAG3 plasmids containing p85-wt and p85-R274A cDNA (Chamberlain et 
al., 2004; King et al., 2000) were grown in selection media (DMEM  + 10% FBS + P/S) 
containing 400 %g/mL Geneticin (G418, Gibco). 
 
3.2 Methods 
3.2.1 Protein Analysis 
3.2.1.1 Sodium dodecyl sulphate (SDS)-polyacrylamide gel electrophoresis (PAGE) 
For protein visualization by either Coomassie blue staining or Western blot analysis, 
proteins were resolved by SDS-PAGE using the Mini-Protean II apparatus (Bio-Rad) 
(Laemmli, 1970).  SDS-PAGE consists of two parts for each gel; resolving and stacking.  The 
resolving gel contained between 7.5%-15% acrylamide solution (29.2:0.8 acrylamide: 
bisacrylamide, 37 mM Tris-HCl pH 8.8 and 0.1% (w/v) SDS) was poured and polymerized first 
by the addition of 0.06% (w/v) ammonium persulfate (APS, Sigma) and 0.1% (v/v) N,N,N’,N’-
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Tetra-methylethylenediamine (TEMED, Bio-Rad).  Water-saturated butan-1-ol (100 %l, Bio-
Rad)) was added to the top of the resolving gel to keep air away from the gel during 
polymerization.  After polymerization (45 min), the butan-1-ol was removed and replaced with 
a two mL stacking gel containing 4.5% acrylamide solution, 125 mM Tris-HCl pH 6.8 and 
0.1% (w/v) SDS.  The stacking gel was also polymerized by the addition of APS and TEMED, 
but was let to sit for only eight min instead of 45 min.  A 15-well teflon comb was inserted into 
the stacking gel to form wells.  After the completed gel was cast, the gel was assembled into the 
electrophoresis apparatus.   The protein samples were prepared in SDS sample buffer (62.5 mM 
Tris-HCl pH 6.8, 5% (v/v) "-mercaptoethanol, 2.3% (w/v) SDS, 0.1% (w/v) bromophenol blue, 
10% (v/v) glycerol) and were heated for five min at 100°C.  Prestained molecular weight 
markers (Fermentas, #SM0671, 170, 130, 100,70, 55, 40, 35, 25, 15, 10 kDa) or unstained 
molecular weight markers (Fermentas, #SM0661, 200, 150, 120, 100, 85, 70, 60, 50, 40, 30, 25, 
20, 15, 10, kDa) and the protein samples were loaded onto the gel and resolved by 
electrophoresis at a constant voltage of 180 V in running buffer (25 mM Tris, 250 mM glycine 
and 0.1% (w/v) SDS) until the bromophenol blue dye was off the bottom of the gel (Laemmli, 
1970).  To visualize the proteins within the gel, the gel was stained with Coomassie blue stain 
(0.14% (w/v) Coomassie blue R-250, 41.4% (v/v) methanol and 5.4% (v/v) acetic acid) for 30 
min at room temperature (RT) with shaking and destained (41.4% (v/v) methanol and 5.4% 
(v/v) acetic acid) until the protein bands were visible.  A picture of the gel was taken using a 
Gel Doc 2000 (Bio Rad). 
 
3.2.1.2 Western blot analysis 
Following electrophoresis (section 3.2.1.1) the SDS-PAGE gel was incubated for 15 
min in transfer buffer (48 mM Tris pH 9.2, 39 mM glycine, 0.0375% (w/v) SDS, 20% (v/v) 
methanol).  During the incubation, six pieces of 3MM filter paper (Whatman) were soaked in 
transfer buffer and one piece of nitrocellulose membrane (Scheicher and Schuell) was soaked 
in distilled water.  A Panter semi-dry Electroblotter Owl Separation System (VWR) was used at 
a constant current of 400 mA (15 min/gel being transferred) to transfer the proteins from the gel 
to the nitrocellulose membrane.  Following the transfer, the nitrocellulose membrane was 
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blocked for one hour at RT or overnight at 4°C in blocking solution (5% Carnation skim milk 
powder in TBST (100 mM Tris-HCl pH 8, 150 mM NaCl, 0.05% polyoxyethylenesorbitan 
monolaurate (Tween-20))).  After blocking, the membrane was probed with primary antibody 
in blocking solution overnight at 4°C at the concentrations listed in Table 3.1.  The membrane 
was then washed three times in TBST for eight min each and incubated with a secondary 
antibody conjugated to horseradish peroxidise (1:2000) for either one hour at RT (or overnight 
at 4°C) and washed three times in TBST for five min each.  The nitrocellulose membrane was 
incubated for one min in Western Lighting enhanced chemiluminescence reagent (Perkin 
Elmer) and in a dark room exposed to X-Omat Blue XB-1 film (Kodak).  Exposures ranged 
from one sec to 30 min.  The film was developed using a Kodak M35A X-Omat processor. 
To reprobe the membrane with different primary antibodies, the membrane was 
incubated in stripping buffer (62.5 mM Tris-HCl pH 6.8, 2% (w/v) SDS, 100 mM "-
mercaptoethanol) for 30 min at 60°C.  The membrane was washed three times in TBST for five 
min and incubated in blocking solution.  The nitrocellulose membrane was reprobed as 
described above. 
 
3.2.1.3 Induction and purification of GST fusion proteins 
 E. coli BL21 cells transformed with the pGEX6P1 vector encoding the protein of 
interest was inoculated into LBA (100 mL) and allowed to grow overnight at 37°C with 
shaking (300 rpm).  The entire overnight culture was added to one litre of LBA and allowed to 
grow at 37°C with shaking (300 rpm) until an OD600 value of 0.5-0.7 was reached.  To induce 
the expression of the GST fusion protein, IPTG (Sigma) was added to a final concentration of 
0.1 mM and the one litre culture was allowed to grow for four hours at 37°C with shaking (300 
rpm).  The cells were pelleted by centrifugation at 6000 x g for 15 min at 4°C.  The one litre 
culture pellets were either lysed immediately or frozen at -20°C until use.    
 
3.2.1.3.1 GST-p85 fusion protein purification 
For cell lysis, culture pellets were weighed and resuspended in PreScission buffer (150 
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mM NaCl, 1 mM ethylenediaminetetraacetic acid (EDTA), 1 mM dithiothreitol (DTT), 50 mM 
Tris-HCl, pH 7.0) (8 mL/1.6 g cells).  Lysozyme (IGN Biochemicals) was added to a final 
concentration of 1 mg/mL and cells were lysed on ice for 45 min.   Cells were sonicated three 
times 30 sec on a setting of 3.0 using a microtip and a Model 250/450 Sonifier (Branson 
Ultrasonics) with two min of chilling on ice between each treatment.  Triton X-100 (Sigma) 
was added to a final concentration of 1% (v/v) to decrease bacterial protein interactions.  Cell 
lysates were centrifuged at 22 000 x g for 30 min at 4°C to remove insoluble material and 
unbroken cells.  The supernatant was filtered using a 0.45 %M cellulose acetate membrane 
(Nalgene) to remove particulates and was incubated with one mL of glutathione Sepharose 
beads (50% slurry) (Amersham Pharmacia Biotech) for one hour at RT with agitation.  GST 
fusion proteins bound to beads were pelleted by centrifugation at 675 x g for 5 min at 4°C.  
Beads were washed six times, each time in 30 mL PreScission buffer and transferred to a 1.5 
mL microcentrifuge tube in a total volume of one mL (50% slurry).   
 For protein purification, the GST tag was cleaved from the GST-p85 wild type and 
GST-p85 mutant fusion proteins using PreScission protease (Amersham Pharmacia Biotech; 
40-160 %L/1 litre culture, determined empirically) 16-64 hr at 4°C with nutating.  The cleaved 
protein fraction was recovered from the supernatant the next day by centrifugation of the beads 
at 2000 x g for five min at 4°C.  The beads were washed six times with one mL PreScission 
buffer to recover any of the cleaved protein trapped in the beads, until an absorbance of <0.1 at 
OD280 was reached in the washes.  Individual aliquots of the cleaved fraction (5 %L each), of 
each wash containing cleaved protein (5 %L each) and beads before and after cleavage (5 %L 
each), were resolved by SDS-PAGE (7.5%-15%) and visualized by Coomassie Blue staining to 
determine protein yield and cleavage efficiency.  The cleaved protein fractions and washes 
containing the desired protein were pooled into an Amicon Ultra Centrifugal Filter (molecular 
weight cut off 5-30 kDa, Millipore), the buffer was replaced with a protein storage buffer (20 
mM Tris-HCl pH 8.0, 100 mM NaCl, 1 mM DTT and 1 mM EDTA) and the sample volume 
was reduced to 800 %L.  Glycerol (to 20% v/v) was added to the protein to decrease protein 
shearing during freezing.   
To decrease non-specific binding to GST and glutathione Sepharose beads during pull-
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down experiments, concentrated p85 proteins were precleared by incubation with 500 %g GST 
bound to glutathione Sepharose beads + 100 %L glutathione Sepharose beads (50% slurry) 
overnight at 4°C.  GST immobilized on beads and any non-specific binding proteins were 
removed from the p85 preparations by centrifugation at 12 000 x g for 10 min at 4°C.  The 
supernatant containing the purified p85 wild type and p85 mutants were precleared three times 
each.  The protein concentrations were determined by Lowry assay (Sigma) according to the 
manufacturer’s instructions.  Protein aliquots were flash frozen in liquid nitrogen prior to 
storage at -80°C for future use in pull-down experiments.   
 
3.2.1.3.2 Preparation of GST-Rab5 fusion proteins bound to glutathione Sepharose beads 
for pull-down experiments   
For the preparation of GST alone (control) and GST-Rab5 mutants bound to beads, 50 
mL culture pellets were obtained by resuspending the one litre culture pellet prior to any 
freezing (Section 3.2.1.3) in 10 mL of phosphate buffered saline (PBS, 137 mM NaCl, 2.7 mM 
KCl, 4.3 mM Na2HPO4, 1.4 mM KH2PO4, pH 7.3) + protease inhibitors (1 mM 4-(2-
Aminoethyl) Benzenesulfonyl Fluoride Hydrochloride, 10 %g/mL aprotinin and 10 %g/mL 
leupeptin)  and then dividing the suspension into 500 %L aliquots in 1.5 mL microcentrifuge 
tubes.  The cells were pelleted by centrifugation at 12 000 x g for two min at 4°C and the 
supernants were discarded.  Samples were either lysed immediately or frozen at -20°C until 
use.  For cell lysis, culture pellets (i.e. 50 mL culture worth) were resuspended in one mL PBS 
+ protease inhibitors and sonicated (section 3.2.1.1.1) three times 10 sec on a setting of 1.5.  
Cell lysates were centrifuged at 12 000 x g for 10 min at 4°C to remove insoluble material and 
unbroken cells.  The supernatant was incubated with 200 %L of glutathione Sepharose beads 
(50% slurry) (Amersham Pharmacia Biotech) and agitated for one hour at RT.  GST fusion 
proteins bound to beads were pelleted by centrifugation at 2000 x g for two min at 4°C.  Beads 
were washed three times each in one mL PBS and made up to a final volume of 500 %L 
suspensions.  The beads were diluted 1/10 in a new microcentrifuge tube and 2-10 %L of 
protein suspensions were resolved by SDS-PAGE (12 %) and visualized using Coomassie Blue 
staining to determine protein purity and concentration.  The protein concentration was 
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estimated by comparison with bovine serum albumin (BSA) standards (0.5-8.0 %g) resolved 
along side the protein of interest.  All protein-bead suspensions were stored at 4°C and were 
stable for up to three weeks.  Protein stability was checked weekly by resolving the proteins on 
an SDS-PAGE gel and staining the proteins using Coomassie Blue staining to check for 
degradation. 
 
3.2.1.4 Pull-down experiments 
 The p85 wild type and p85 mutant proteins were further precleared with GST bound to 
glutathione Sepharose beads (200 %g GST immobilized on glutathione Sepharose beads) and 
50 %L glutathione Sepharose beads (50% slurry) for two hours at 4°C.  During p85 wild type 
and p85 mutant protein preclearing, GST (10 %g), GST-Rab5-Q79L (10 %g), and GST-Rab5-
S34N (10 %g) bound to glutathione Sepharose beads were added to separate microcentrifuge 
tubes.   An extra 30 %L of glutathione Sepharose beads (50% slurry) were added to each tube to 
increase the bead pellet for easy visualization.  The beads were washed with 500 %L of dilution 
buffer (20 mM Tris-HCl pH 7.5, 1 mM DTT, 5 mM MgCl2, 20% (v/v) glycerol).  The beads 
were collected by centrifugation at 2000 x g for two min at 4°C and the supernatant was 
removed.  The beads were incubated with 500 %L Buffer A (20 mM Tris-HCl pH 7.5, 1 mM 
DTT, 10 mM EDTA, 5% (v/v) glycerol, 0.1% (v/v) Triton X-100, 10 %g/ml leupeptin, 10 
%g/ml aprotinin) for 20 min at RT to strip off any nucleotide bound to the GST-Rab5 proteins.  
The beads were collected as described above and the supernatants removed.  The beads were 
incubated in 400 %L of Buffer B/C (20 mM Tris-HCl pH 7.5, 1 mM DTT, 10 mM MgCl2, 5% 
(v/v) glycerol, 0.1% (v/v) Triton X-100, 0.1% (v/v) Tween-20, 10 %g/mL leupeptin, 10 %g/mL 
aprotinin) + the nucleotide indicated below for 30 min at RT: 
1. GST (negative control) had no nucleotide added. 
2. GST-Rab5-Q79L was incubated with 200 %M guanosine 5` triphosphate (GTP, Sigma). 
3. GST-Rab5-S34N was incubated with 200 %M guanosine 5` diphosphate (GDP, Sigma). 
The beads were collected as described above and the supernatant removed.  The beads were 
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blocked in 500 %L blocking solution (5% Carnation skim milk powder in Buffer B/C + 
nucleotide as described above) for 30 min at 4°C.  After 20 min of this blocking step, the 
precleared p85 wild type and p85 mutant proteins were centrifuged at 12 000 x g for 10 min at 
4°C to separate the protein in the supernatant from the preclearing beads (discarded).  For the 
protein binding reaction, either p85 wild type (1 %g) or p85 mutants (1-10 %g) were added 
directly to the blocking beads and allowed to bind for one hour at 4°C.  The beads were 
collected as described above and washed three times each with one mL IP-Wash buffer (50 
mM Tris-HCl pH 7.5, 150 mM NaCl, and 1% (v/v) onidet P40 (NP-40, USB).  Washes ranged 
from 10 sec to five min with or without nutating.  The beads were collected as described above, 
supernatant removed and SDS sample buffer (15 %L) was added.  The samples were frozen at -
20°C until use or immediately resolved by SDS-PAGE (Section 3.2.1.1) followed by Western 
blot analysis (Section 3.2.1.2). 
 
3.2.2 Molecular Biology 
3.2.2.1 Polymerase chain reaction (PCR) 
Primers (Invitrogen) were designed to amplify the cDNA corresponding to the BH 
domain of the p85 subunit of PI3K.  A unique restriction enzyme site was incorporated at both 
the 3` and 5` ends for easy subcloning.  There were four primers designed to amplify the 
regions encoding the BH domain plus the N-terminal proline rich region (p85-Pro-BH), the C-
terminal proline rich region (p85-BH-Pro) or to exclude both regions (p85-BH). These are 
described in Table 3.2.  For the PCR reaction, 0.5 mL microcentrifuge tubes were used.  The 
reaction was carried out in a total volume of 100 %L.  The following were added to the PCR 
reaction (final concentrations):  1x Pfu buffer (Fermentas), 5% (v/v) dimethyl sulfoxide, 0.02 
mM dNTPs (each), 10 ng template pGEX6P1-p85 wild type DNA, 0.1 %M 5` primer, 0.1 %M 
3` primer and 2.5 units Pfu enzyme (Fermentas).  The PCR reaction was initially set at 95°C for 
4 min.  This was followed by 40 cycles of 95°C for 30 sec (to denature double stranded 
template DNA and primers), 56°C for 30 sec (to anneal the primers to the template DNA), and 
72°C for one min (to extend the DNA).  A final 72°C step (for seven min for further DNA 
extensions) was included.  Aliquots of the PCR product (10 %L), 1 kb DNA ladder (Fermentas,  
Table 3.2.  Primers used to amplify the p85-BH domain with and without the
Pro-rich regions
p85
domain
Amino
Acids
Encoded
5 ` primer 3 ` primer
p85-
Pro-BH
79-301
5´-ACC ACA AAG GAT CCG GAA GGA
AAA AGA TCT CGC CTC CCA-3´
5´-CCA GAA TTC GCG TTC ATT
CCA TTC GG-3´
p85-
BH-Pro
110-332
5´-GCA GGA TCC CAA CAA GCT TCC
ACT CTC-3´
5´-CAT CAC GGG AAT TCA TTC
AGC ATC TTG TAA AGA CAT ATT-
3´
p85-BH 126-298
5´-GCA GGA TCC CAA CAA GCT TCC
ACT CTC-3´
5´-CCA GAA TTC GCG TTC ATT
CCA TTC GG-3´
EcoRI Site
BamHI Site
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#SM0313, 10000, 8000, 6000, 5000, 4000, 3000, 2500, 2000, 1500, 1000, 750, 500, 250) and 
100 bp DNA ladder (Fermentas, #SM0243, 1031, 900, 800, 700, 600, 500, 400, 300, 200, 100, 
80) were resolved on a 1% agarose gel (0.4 g agarose in 1x Tris Acetic Acid EDTA (TAE, 40 
mM Tris acetate and 2 mM Na2EDTA) and 1 %g/mL ethidium bromide) at a constant current of 
100 V for 25 min to check for the presence and size of the PCR product.  The remaining PCR 
product was visualized using a Gel Doc 2000 (Bio Rad).  The PCR product was purified using 
a QIAquick PCR Purification kit (Qiagen) following the manufacturer’s instructions.   
 
3.2.2.2 Digestions and ligations 
The inserts encoding the p85-Pro-BH, p85-BH-Pro, and p85-BH amplified by PCR had 
a unique restriction enzyme site incorporated at each end during amplification:  BamHI at the 
5` end and EcoRI at the 3` end.  The p85-Pro-BH, p85-BH-Pro, and p85-BH encoding DNA 
were inserted into the multiple cloning site of the pGEX6P1 vector using the BamHI and EcoRI 
restriction sites.  The pGEX6P1 was chosen as it would produce GST fusion proteins for easy 
purification later on.  The p85-Pro-BH, p85-BH-Pro, p85-BH encoding PCR inserts, and 
pGEX6P1 vector DNA were digested separately in a total volume of 40 %L.  The following was 
added to the digestion reaction (final concentrations):  1x Phorall buffer (Amersham Pharmacia 
Biotech), 2 %g of the individual PCR product or pGEX6P1 vector DNA, 20 units BamHI (New 
England Biolabs), and 20 units EcoRI (New England Biolabs).  The reactions were incubated at 
37ºC for one hour.  The digested products were purified using a QIAquick PCR Purification kit 
(Qiagen) following the manufacturer’s instructions but eluted in a smaller volume of 25 %L.  
An aliquot of the newly digested cDNA (2 %L) was resolved on a 1% agarose gel and 
visualized as described (Section 3.2.2.1).   
The p85-Pro-BH, p85-BH-Pro, p85-BH encoding cDNA concentrations were compared 
to the restricted pGEX6P1 vector DNA to perform the ligation reaction.  For the ligation 
reaction 6x molar excesses insert DNA was added to the vector DNA (~200 ng) with 10 %L of 
2x Quick ligation buffer (New England BioLabs) in a total volume of 20 %L.  To start the 
reaction, one %L of Quick T4 DNA Ligase (New England BioLabs) was added and allowed to 
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sit for 20 min at RT.   
To express the clonal product, 10 %L of the ligation mix was added to competent E. coli 
TOP10 (200 %L) cells (Hanahan, 1983) and incubated on ice for 10 min.  The plasmid DNA 
was transformed into the E. coli TOP10 cells by heat shocking the cells at 42ºC for two min 
followed by five minute incubation on ice.  LB (800 %L) was then added to the cells and they 
were incubated at 37ºC for 30 min to allow expression of the plasmid.  The cells successfully 
expressing the plasmid DNA were selected for by plating the cells onto an LBA agar plate 
(LBA + 0.02% agar (w/v), Sigma).  The cells grew overnight at 37ºC.   
To confirm the pGEX6P1 vector contained the proper insert, E. coli TOP10 colonies 
were inoculated into five mL LBA and grown overnight at 37ºC.  Plasmid DNA was isolated 
from overnight cultures using a QIAprep Spin Miniprep Kit (Qiagen) as per the manufacturer’s 
instructions.  The plasmid DNA (2 %L of 50 %L preparation) was digested with BamHI (10 
units) and EcoRI (10 units) as described above, and the digests were resolved on a 1% agarose 
gel and visualized as described (Section 3.2.2.1).  Plasmids containing inserts were sequenced 
to ensure there were no mutations in the insert introduced during the PCR reaction.  The DNA 
was sent to the National Research Council of Canada Plant Biotechnology Unit for sequencing.   
The plasmid DNA that contained both the vector and insert of the proper size was 
transformed into E. coli BL21 for future induction (Section 3.2.1.3) and purification of GST 
fusion proteins (Section 3.2.1.3.1).   
 
3.2.3 Cell Culture Techniques 
3.2.3.1 Growth factor stimulations 
NIH 3T3 cells and NIH 3T3 cells stably expressing FLAG-p85 wild type and FLAG-
p85-R274A were grown to 70% confluency on 10 cm plates.  The cells were starved in starving 
media (DMEM + 0.5% FBS + P/S) for 24 hours at 37°C.  After 24 hours, two mL of starving 
media were removed from each plate of cells and PDGF was added to a final concentration of 
50 ng/mL.  The remainder of the starving media was removed from each plate of cells and 
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replaced with the two ml of starving media + PDGF.  Cells were stimulated for 0, 5, 10, 20, 30, 
or 60 min at 37°C.  After stimulation, the cells were placed on ice, washed with five mL ice 
cold PBS and each plate was lysed in one mL of PLC lysis buffer (50 mM Hepes pH 7.5, 150 
mM NaCl, 10% (v/v) glycerol, 1% (v/v) Triton X-100, 1.5 mM MgCl2, 1 mM ethyleneglycol-
bis (B-aminoethylether) N,N,N,N, tetraacetic acid (EGTA), 10 mM sodium pyrophosphate 
(NaPPi), and 100 mM NaF) + protease inhibitors + 1 mM sodium orthovanadate (Na3VO4, 
Sigma).  The lysed cells were scraped and transferred to a 1.5 mL microcentrifuge tube.  The 
cell debris and unbroken cells were removed by centrifugation at 12 000 x g for 10 min at 4°C.  
The supernatant containing soluble protein was transferred to a new microcentrifuge tube and 
frozen at -80°C. 
 
3.2.3.2 PDGFR immunoprecipitations 
After cell stimulations (Section 3.2.3.1), the PDGFR was immunoprecipitated from the 
cell lysates.  The protein concentration from the cell lysates was determined by Lowry assay 
(Sigma) according to the manufacturer’s instructions.  The cell lysates (500 %g) were 
transferred to new microcentrifuge tubes.  The lysates were precleared, to decrease any non-
specific binding, with anti-rabbit IgG agarose conjugate (5 %g, Santa Cruz Biotechnology, sc-
2345) and either 30 %L of Protein A Sepharose beads (Sigma), 30 %L of Protein G Agarose 
beads (Sigma) or 50 %L of TrueBlot beads (eBioscience) for 30 min at 4°C.  The beads and 
non-specifically associating proteins were removed by centrifugation at 12 000 x g for 10 min 
at 4°C.  The supernatant was incubated with anti-PDGFR 958 (5 %g, Santa Cruz 
Biotechnology, sc-432) and either 30 %L of Protein A Sepharose beads (Sigma), 30 %L of 
Protein G Agarose beads (Sigma) or 50 %L of TrueBlot beads (eBioscience) for 1.5 hours at 
4°C.  The beads were centrifuged at 2000 x g for two min at 4°C and washed three times each 
in one mL HNTG (20 mM HEPES, pH 7.5, 150 mM NaCl, 0.1% (v/v) triton X-100, 10% (v/v) 
glycerol, + 1 mM Na3VO4 (Sigma) and centrifuged as described above.  The supernatant was 
discarded and SDS sample buffer (15 %L) was added to the beads.  The samples were frozen at 
-20°C until use or immediately resolved by SDS-PAGE (7.5%) (Section 3.2.1.1) for Western 
blot analysis (Section 3.2.1.2). 
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3.2.3.3 Biotin assay 
NIH 3T3 cells and NIH 3T3 cells stably expressing FLAG-p85 wild type and FLAG-
p85-R274A were grown to 70% confluency on 10 cm plates.  The cells were starved in starving 
media (DMEM + 0.5% FBS + P/S) for 24 hours at 37°C.  After 24 hours, two ml of starving 
media were removed from each plate of cells and PDGF was added to 50 ng/mL.  This media 
was left at 37°C until use.  Controls included: 
1. MOCK - not treated with biotin, unstimulated and kept at 4°C during the entire 
experiment to assess how much receptor is non-specifically recovered by the 
streptavidin IP in the absence of any biotin labelling. 
2.  4°C – treated with biotin and stimulated as long as the longest time point of the 
experiment, however kept at 4°C (on ice) during the experiment to prevent 
endocytosis and to assess how much endocytosis is occurring at 4°C (on ice). 
3. 0 min stimulation – treated with biotin and not stimulated, therefore kept on ice 
for the entire experiment to assess how efficiently the biotin label is removed 
from the cell surface. 
The cells were washed once with five mL 4°C PBS
++ 
(PBS
 
+ 1 mM MgCl2 and 2.5 mM CaCl2).  
Cells were incubated with 1.5 mg/mL EZ-LinkTM Sulfo-NHS-SS-Biotin (biotin, PIERCE, 
#21335) in PBS
++
 for 20 min at 4°C (1.5 mL/10 cm plate).  Cells were washed three times with 
five mL cold 50 mM glycine in PBS
++
 to quench unlinked biotin.  Cells were stimulated with 
the PDGF in starving media (removed earlier) for 0, 10, 20, 30, 40, or 60 min as described 
(Section 3.2.3.1) at 37°C.  The cells were placed on ice and washed three times with five mL 
cold PBS
++ 
followed by three washes with five mL ice cold glutathione cleavage buffer (50 
mM L-glutathione reduced (Sigma), 75 mM NaCl, 10 mM EDTA, 1% fatty acid free BSA 
(w/v), and 0.075 N NaOH) to cleave surface biotin.  Cells were washed three times with five 
mL ice cold 5 mg/mL Iodoacetamide in PBS
++
 to quench the reaction.  Cells were washed once 
with five mL PBS
++
 and lysed as described (Section 3.2.3.1).  Biotinylated proteins (150 %g as 
determined by lowry) were immunoprecipiated as described (Section 3.2.3.2) with 50 %L 
UltraLink Immobilized Strepavidin (PIERCE) beads overnight at 4°C.  The beads were washed 
three times each in five mL HNTG discarding the supernatant.  SDS sample buffer (20 %L) was 
added to the beads.  The samples were frozen at -20°C until use or immediately resolved by 
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SDS-PAGE (7.5%, note 1.5 mm thick) (Section 3.2.1.1) followed by Western blot analysis 
(Section 3.2.1.2). 
 
3.2.3.4 Immunofluorescence and confocal microscopy 
NIH 3T3 cells and NIH 3T3 cells expressing FLAG-p85 wild type and FLAG-p85-
R274A were seeded onto a four-well chamber slide (VWR, CA62405-176) (1.0 x 10
4
 
cells/well).  The next day the cells were incubated in one mL starving media overnight and 
were about ~60% confluent.  The cells were stimulated with PDGF as described previously (50 
ng/mL, 300 %L/well) for 0, 10, 30 or 120 min at 37°C.  The media was removed from each well 
and the cells were washed twice with one mL PBS + 1 mM sodium azide (NaN3, BDH).  The 
cells were fixed with 500 %L 14% paraformaldehyde in PBS for 30 min at RT.  The 
paraformaldehyde was removed and the cells were washed three times with one mL PBS + 
NaN3.  The cells were incubated undisturbed with 500 %L 0.05% saponin (Sigma) in 
PBS+NaN3+ 1% BSA for 30 min at RT to permeabilize the cells.  The cells were washed three 
times in one mL PBS+NaN3+BSA.  The cells were incubated with primary antibody (anti-
PDGFR 958 (0.5 %g/mL, Santa Cruz Biotechnology, sc-432), anti-Rab5 (1 %g/mL, Abcam, 
#ab50523), anti-Rab4 (3 %g/mL, BD Transduction Laboratories, #610888), anti-
phosphoPDGFR (pY857) (0.5 %g/mL, Santa Cruz Biotechnology, sc-12907-R)) as indicated in 
each figure overnight at 4°C.  When probing with more than one primary antibody at a time, it 
was important that each was raised in a different species (mouse or rabbit) for accurate binding 
of the fluorescently tagged secondary antibody.  The next day, the cells were washed three 
times with one mL PBS+NaN3+BSA.  On the last wash, the cells were incubated in one mL 
PBS+NaN3+BSA for 10-20 min nutating slowly at RT.  The Alexa 488 (green) or Alexa 594 
(red) (5 %g/mL, Molecular Probes) secondary antibodies were added to each well and allowed 
to incubate at RT in the dark.  When probing with more than one secondary antibody at a time, 
it was important that each secondary antibody recognized different species (mouse or rabbit) 
and that each secondary antibody was represented by a different fluorophore (red or green) for 
accurate identification later on.   The cells were washed in the dark as described after the 
primary antibody.  Once the washing was complete, the chamber portion of the chamber slide 
69 
 
was removed to isolate the slide.  The slide was dried completely in the dark and a single large 
cover slip (VWR, #48393241) was mounted onto the slide using ProLong Gold antifade 
reagent/mounting medium (Invitrogen).  The slides were stored in the dark at either 4°C for 
short term storage or -20°C for longer storage. 
Immunofluorescence images were generated using an Olympus F300 confocal 
microscope (Dr. Mousseau, Dept. Of Psychiatry, University of Saskatchewan) using an 
UPLanSApo 100x oil immersion objective with a numerical aperture of 1.40.  Images were 
selected based on representative cells showing high fluorescence intensity to insure there was 
no bleed through from the red channel to the green channel when two antibodies were used.  
The fluorescence intensity (PMT setting) was adjusted to decrease or increase the red or green 
fluorescence to make them similar to each other.  To decrease background, the Gain and Offset 
settings were also adjusted.  After the primary settings were identified, cells were analyzed by 
fast Z-sectioning (XYZ) taking image slices through the cell at different depths.  Once the 
middle of the cell was identified, cells were analyzed by slow Z-sectioning (XY) and Kalman 
analysis.  Several scans at the same depth were taken and the intensities for each were averaged 
to generate one image.  The picture was saved and the process was repeated for all other cells 
in the experiment using the exact same settings. 
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4.0 RESULTS 
4.1 Interaction of p85 with Rab5 
The p85 wild type protein can bind to Rab5 directly (Chamberlain et al., 2004).  It has 
been shown that p85 wild type can bind to both the inactive Rab5-GDP conformation and the 
active Rab5-GTP conformation, while some p85 mutants show a strong preference for only 
Rab5-GDP or Rab5-GTP (Chamberlain et al., 2004).  To characterize the function of the 
p85:Rab5 interaction in cells, the aim of this work was to generate a p85 mutant unable to bind 
Rab5 by focusing on which domains of p85 were needed for Rab5 binding. 
 
4.1.1 Purification of wild type and p85 mutant proteins 
The p85 regulatory subunit is made up of five domains.  To determine which domains 
of p85 were required for Rab5 binding, mutant p85 proteins were made which contained one or 
more domains of p85 in different combinations (p85-wt, p85-R274A, p85-SH3, p85-SH3+Pro-
BH-Pro, p85-Pro-BH-Pro, p85-(BH, p85-(110, p85-N-SH2, p85-C-SH2, p85-(N+C)SH2, 
p85-p110B, p85-(SH3) (Fig. 4.1).  Purified proteins were needed to assay the direct interaction 
between p85 and Rab5.  GST-p85 proteins were bacterially expressed, bound to glutathione 
Sepharose beads, and the p85 portion was cleaved from the GST using a PreScission protease.  
Isolated p85 proteins were concentrated using Amicon Ultra filters.  The p85 preparations were 
precleared by incubation with GST (500 %g) bound to glutathione Sepharose beads overnight at 
4ºC.  Proteins were precleared three times to decrease non-specific interactions between the 
p85 preparations and the GST and/or glutathione Sepharose beads.   Protein concentrations 
were determined and the p85 proteins were resolved using SDS-PAGE.  The p85 proteins were 
visualized by Coomassie Blue staining as well as Western Blot analysis (Fig. 4.2).  The 
proteins obtained were approximately 90-100% pure.  The smaller bands present in lanes 1, 2, 
9, 13, 14, and 15 are likely degradation products of the p85 proteins possibly due to freezing 
and thawing the proteins for storage, since they react with the anti-p85 antibodies (Fig. 4.2B).  
 
Fig. 4.1.  Domain stucture of p85-wt and p85 mutants.  The p85 mutants were
overexpressed in bacterial systems as glutathione S-transferase (GST) fusion
proteins.  GST-p85 fusion proteins were isolated by binding to glutathione
Sepharose beads.  The p85 proteins were cleaved from the GST rendering purified
proteins.
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Fig. 4.2. Purified p85 protein domains.  Bacterially expressed GST-p85 fusion
proteins were induced for 4 hrs at 37ºC with 0.1 mM of IPTG. Proteins were bound
to glutathione Sepharose beads and removed from GST using PreScission cleavage.
Isolated p85 proteins were concentrated using 5000-30000 MWCO Amicon Ultra
filters. Protein concentrations were determined and 1 !g of each protein was
resolved using SDS-PAGE.  The proteins were visualized by A) Coomassie Blue
stain with unstained kDa molecular weight markers (Fermentas, #SM0661) and B)
Western Blot analysis with prestained kDa molecular weight markers (Fermentas,
#SM0671). The p85 proteins were transferred to nitrocellulose, blocked and probed
with anti-p85-N-SH3, anti-p85-BH, and anti-p85-(N+C)SH2 antibodies.  Bound
antibodies were detected using IgG-linked to horseradish peroxidase and visualized
using chemilluminescence.  Where multiple bands were observed, an arrow
indicates the size of the full-length protein.
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4.1.2 GST-Rab5 pull-down experiments using different p85 domains 
The ability of different domains of p85 to bind to Rab5, as well as their preference for 
the inactive Rab5-GDP or active Rab5-GTP conformations was tested.   Two Rab5 mutants 
were used which preferentially bound either GTP or GDP (Liu and Li, 1998).  GST-Rab5-
S34N bound GDP and GST-Rab5-Q79L bound GTP.  Mutant GST-Rab5-S34N and GST-
Rab5-Q79L were bacterially expressed as GST fusion proteins and were immobilized on 
glutathione Sepharose beads along with a GST negative control for the GST pull-down 
experiments (Fig. 4.3).  Each immobilized GST-Rab5 mutant was loaded with its respective 
nucleotide.  GST, GST-Rab5-S34N and GST-Rab5-Q79L were incubated with purified p85 
proteins in a solution containing 5% milk blocking reagent.  The beads were then washed and 
samples were resolved using SDS-PAGE.  Control samples consisting of GST and Rab5 bound 
to glutathione Sepharose beads without incubation with p85 proteins were also resolved by 
SDS-PAGE.  Control samples were loaded to ensure there was no cross reactivity between the 
anti-p85 antibodies with the GST-Rab5 proteins and/or non-specific binding of p85 to GST 
and/or the glutathione Sepharose beads.  A Western Blot analysis was performed using p85 
protein specific antibodies (Fig. 4.4).   
Initially there were twelve p85 proteins (Fig. 4.1) tested for Rab5 binding.  Of these 
twelve p85 mutants:  four did not bind either Rab5 mutant (N-SH2, C-SH2, p110B and SH3), 
two bound significantly better to Rab5-GDP (R274A and (110), two bound better to Rab5-
GTP ((BH and Pro-BH-Pro) and two bound to both Rab5 mutants (p85-wt and (N+C)SH2) 
though the p85-(N+C)SH2 was not as convincing (Fig. 4.4).  The remaining two p85 mutants 
(SH3-Pro-BH-Pro and (SH3) proved difficult to test due to non-specific binding interactions 
with the GST control sample (Fig. 4.5).  Samples p85-wt, p85-R274A, and p85-(BH were 
tested previously and are shown in Fig. 1.18 (Chamberlain et al., 2004).  As each protein 
behaved differently, optimizing the experiments to decrease non-specific interactions was a 
large problem.  Numerous combinations and concentrations of salt and detergents (20 mM Tris-
HCl pH 7.5, 1 mM DTT,  5 or 10 mM MgCl2,   10 mM EDTA, 50-150 mM NaCl, 0.1%-1% 
Triton-X 100, and 0.1%-1% Tween 20)  within the buffers were altered.  Numerous washing 
conditions (10 sec-5 x 5 min washes in IP wash buffer (50 mM Tris-HCl pH 7.5, 150-500 mM  
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Fig. 4.3. GST and GST-Rab5 fusion proteins bound to glutathione Sepharose
beads.  Bacterially expressed GST-Rab5 fusion proteins were induced for 4 hrs
at 37ºC with 0.1 mM of IPTG. Proteins were bound to glutathione Sepharose
beads and 5 !g of each was resolved using SDS-PAGE.  The proteins were
visualized by Coomassie Blue stain.
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Fig. 4.4. GST-Rab5 pull-down experiments using different p85 domains.
GST, GST-Rab5-S34N and GST-Rab5-Q79L (10 !g) were loaded with their
respective nucleotide, and were incubated with 5 µg of purified p85 proteins in a
500 µl solution containing 5% milk blocking reagent.  Samples recovered with the
beads were resolved using SDS-PAGE. Western Blot analysis was performed
using p85 protein specific antibodies ( *** anti-p85-(N+C)SH2, * anti-p85-N-
SH3,  and ** anti-p85-BH).  Samples p85, p85-"BH and p85-R274A were
supplied by Chamberlain et. al., 2004 and are shown in Fig. 1.18. Red lettering
represents p85 domains which have bound Rab5 mutants.  Results are
representative of three independent experiments.
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Fig. 4.5. p85 mutants bind non-specifically with the GST negative control in
pull-down experiments. GST, GST-Rab5-S34N and GST-Rab5-Q79L (10 !g) were
loaded with their respective nucleotide, and were incubated with 5 µg of purified
p85 proteins in a 500 µl solution containing 5% milk blocking reagent.  Samples
were resolved using SDS-PAGE and Western Blot analysis was performed using the
p85 protein specific antibody anti-p85-BH. Where multiple bands were observed, an
arrow indicates the size of the correct protein.  Results are representative of three
independent experiments.
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NaCl and 1% NP-40)) and countless protein preclearing steps with 100-500 %g GST 
immobilized on glutathione Sepharose beads overnight at 4°C were performed to try to 
decrease non-specific binding.  The difficulties were not resolved using these strategies. 
The results of the successful binding experiments indicated that there were at least two 
domains of p85 involved in binding to Rab5:  one within the p85-Pro-BH-Pro region and one 
outside of this region, that has not been localized further (Fig. 4.4).  The p85-Pro-BH-Pro 
protein fragment that bound to Rab5 contained the BH domain and two flanking proline-rich 
regions.  To further characterize this interaction, three new protein fragments missing either the 
N-terminal, C-terminal flanking proline-rich regions, or both (BH-Pro, Pro-BH, and BH 
respectively) (Fig. 4.6) were generated.  Each of these proteins was tested to determine whether 
or not the proline rich regions were important for Rab5 binding.  The regions encoding each of 
these p85 proteins were amplified by PCR and the DNA was inserted into a pGEX6P1 vector at 
BamHI and EcoRI sites.  After sequencing the DNA to confirm the integrity of these new 
clones, proteins were bacterially expressed as GST-p85 fusion proteins and cleaved from GST 
as before.  Pull-down experiments were carried out as before.  The p85-BH domain containing 
no proline rich regions bound to Rab5 in its GTP bound state though less well, suggesting that 
these proline rich regions were not absolutely required for Rab5 binding (Fig. 4.7A).  Both p85-
Pro-BH and p85-BH-Pro bound non-specifically to the GST control sample and binding 
specificities could not be resolved (Fig. 4.7B).  The p85-(BH protein, missing the entire Pro-
BH-Pro domain, still bound to Rab5-GTP suggesting additional domain(s) of p85 also 
contribute to Rab5 binding (Fig. 1.18).   
The other important domain contributing to Rab5 binding may be the p85-SH3 domain 
although when used as an isolated domain it did not bind to Rab5 in either active or inactive 
conformation (Fig. 4.4).  Domains comprising the C-terminal portion of the protein (p85-N-
SH2, p85-C-SH2 and p85-p110B) showed no significant binding to Rab5 either (Fig. 4.4).  
Although there may be minimal binding to Rab5 by the p85-(N+C)SH2 domain, the bands 
were shifted on the SDS-PAGE gel suggesting they were of the wrong molecular weight to 
correspond to the p85 protein.  It is possible that the bands seen were background GST-Rab5 
protein cross-reactivity but the control lane where only the GST-Rab5 bound to beads in the  
Fig. 4.6. Domain structure of different p85-BH proteins generated. The p85-
Pro-BH, p85-BH-Pro, and p85-BH encoding DNA  were amplified by PCR and
were inserted into the multiple cloning site of the pGEX6P1 vector using the
restriction sites BamHI and EcoRI.  Proteins were bacterially expressed, isolated by
binding to glutathione sepharose beads and cleaved from GST as described
previously.
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Fig. 4.7.  Contribution of the Pro-rich regions flanking the p85-BH domain to
Rab5 binding. GST, GST-Rab5-S34N and GST-Rab5-Q79L (10 !g) were loaded
with their respective nucleotide, and were incubated with 5 µg of purified p85
proteins in a 500 µl solution containing 5% milk blocking reagent.  Samples were
resolved using SDS-PAGE and Western Blot analysis was performed using an anti-
p85-BH antibody. A) GST pull-down experiment showing the p85-BH domain
containing no Pro-rich regions binds to Rab5. B) p85-Pro-BH and p85-BH-Pro have
non-specific interactions with the negative control in GST pull-down experiments.
Results are representative of three independent experiments.
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absence of added p85, did not show a similar band.  Further characterization of the domains 
responsible for p85:Rab5 binding still needs to be investigated to identify the other important 
domain(s) contributing to Rab5 binding and to fully understand the importance of the selective 
binding of the p85 mutants to inactive and active Rab5 conformations. 
 
4.2 Mechanism as to how expression of the p85-R274A mutant leads to decreased PDGFR 
degradation 
Previously, the activation and PDGFR degradation patterns in NIH 3T3 cells, p85 wild 
type expressing and p85-R274A expressing cells was determined (Chamberlain et al., 2004). 
NIH 3T3 cells expressing the p85-R274A mutant displayed increased and prolonged PDGFR 
activation as compared to both control cells.  The increase in PDGFR activation, as determined 
by tyrosine phosphorylation, resulted in a minor increase in Akt activation and a substantial 
increase in MAPK signalling.  In addition to the increased levels of PDGFR activation and 
downstream signalling, a reduction in PDGFR degradation was observed in cells expressing 
p85-R274A, compared to p85-wt and NIH 3T3 control cells.  The goal of these next studies 
was to determine how PDGFR downregulation was being altered in these cells by examining 
PDGFR monoubiquitination, a modification required for lysosomal sorting, and PDGFR 
degradation.  
 
4.2.1 PDGFR Monoubiquitination 
To determine whether the delayed PDGFR degradation was due to a lack of PDGFR 
ubiquitination, the PDGFR ubiquitination status in each of the cell lines (NIH 3T3, p85-wt, and 
p85-R274A) was studied.  Stable cell lines expressing FLAG-p85-wt, FLAG-p85-R274A and 
control NIH 3T3 cells were tested to determine the effect of p85 mutant expression on PDGFR 
ubiquitination, activation state and degradation. Cells were starved 24 hrs in advance of 
stimulation and stimulated for 0, 5, 10, 20, 30, and 60 min with PDGF. PDGFR was 
immunoprecipitated and samples were resolved using SDS-PAGE. Western blot analysis was 
performed using antibodies specific for ubiquitin, phosphotyrosine, phosphotyrosine1021 (Cbl  
Fig. 4.8.  PDGFR is ubiquitinated but has decreased receptor degradation in
cells expressing the p85-R274A mutant.  Stable cell lines expressing p85-wt, and
p85-R274A and control NIH 3T3 cells were stimulated with PDGF for the
indicated time.  PDGFR was immunoprecipitated and samples were resolved using
SDS-PAGE.  A) Western blot analysis was performed using antibodies specific for
ubiquitin, pTyr, and PDGFR. B) Western blot analysis was performed using
antibodies specific for pY1021 of the PDGFR. C) Western blot analysis was
performed using antibodies specific for FLAG and p85.  Results are representative
of three independent experiments.
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binding site on PDGFR), FLAG, p85 and PDGFR (Fig. 4.8).  
To confirm previous observations of increased and prolonged activation but delayed 
PDGFR degradation displayed by the p85-R274A expressing cells (Chamberlain et al., 2004), 
PDGFR activation state, ubiquitination, and degradation (Fig. 4.8A) levels were examined first.  
Both the p85-R274A and p85-wt expressing cells showed an increase in activation (Fig. 4.8A; 
pTyr blot) as compared to NIH 3T3 cells.  Differences in prolonged activation were evident 
between the p85-R274A expressing cells and the NIH 3T3 cells.  These results did not fully 
agree with those observations seen by Chamberlain et al. (2004) where the p85-R274A cells 
showed a significant difference in prolonged activation as compared to both other cell types 
(Chamberlain et al., 2004).  The discrepancies between the prolonged activation levels seen in 
each cell line could be a result of the type of experiment used in each case.  Chamberlain et al. 
(2004) were looking at PDGFR activation levels using total cell lysates over a four hr time 
course whereas the experiments examined here were of PDGFR IPs over a one hr time course.  
Most of the differences observed by Chamberlain et al. (2004) were observed between the 30 
min to four hr time frame.  Further, the IP experiments provide a sampling of the PDGFR 
present and typically do not recover all of the PDGFR present in the cell lysate.  As such, as the 
total PDGFR levels decrease, the PDGFR IP may recover a greater portion of the total 
receptors remaining in the cell lysate.  Thus, PDGFR IPs are a good way to look for post-
translational modifications on the PDGFR, but are not quantitative if the PDGFR levels are 
changing over time.  In agreement with the observations seen by Chamberlain et al. (2004) the 
p85-R274A expressing cells showed decreased PDGFR degradation as compared to both NIH 
3T3 cells and p85-wt expressing cells.  The PDGFRs in p85-R274A expressing cells showed 
intermediate ubiquitination levels that were greater than those observed in NIH 3T3 cells, yet 
less than in p85-wt expressing cells.  However, cells expressing the p85-R274A mutant showed 
decreased PDGFR degradation compared to that observed in control cells.  This suggests that 
defective ubiquitination, required for lysosomal sorting, was not the cause of the decreased 
PDGFR degradation. 
Knowing the PDGFR was indeed ubiquitinated in all of these cell lines, the ability of 
the PDGFR to associate with several known proteins important for sorting the receptor to the 
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late endosome or lysosome was investigated.  Cbl, Hrs and Eps15 are found at the early 
endosome, whereas STAM and tsg101 are found at the late endosome and lysosome (Urbe, 
2005).  Several of these proteins bind monoubiquitinated protein, including receptors, and are 
themselves monoubuquitinated.  The PDGFR binds, via its phosphorylated Y1021 residue, the 
E3 ubiquitin ligase Cbl (Thien and Langdon, 2001); (Tsygankov et al., 2001). This site was 
phosphorylated in all cell lines after stimulation with PDGF but remained phosphorylated 
longer in p85-R274A expressing cells (Fig. 4.8B).  The PDGFR was ubiquitinated and the Cbl 
binding site was phosphorylated, therefore anti-PDGFR immunoprecipitates were probed for 
Cbl to determine if the protein responsible for conjugating ubiquitin to the PDGFR was 
associated with the PDGFR.  Cbl binding was detected at all time points but it seemed the 
binding detected was a non-specific interaction to either the IP beads used in the experiment or 
the rabbit IgG as the binding was seen even when the cells were unstimulated (i.e. in the 
absence of pY1021 phosphorylation of the PDGFR), as well as in the control anti-rabbit IgG 
immunoprecipitation lanes (Fig. 4.9A).   
Several different IP beads, Protein G Agarose (Sigma) and TrueBlot anti-rabbit Ig IP 
beads (eBiosciences), were tested to decrease the non-specific Cbl binding.  All of the beads 
used were able to strongly bind rabbit derived antibodies.  The Protein G Agarose and TrueBlot 
beads differed from the Protein A beads in that they recognized and bound a different section of 
the rabbit IgG.  The TrueBlot beads system were also different because this system used a 
unique secondary antibody designed to recognize native primary antibody (i.e. the one used to 
probe the blot) and therefore showed less background when immunoblotting since its ability to 
recognize the denatured IP antibody was diminished.  All beads tested still showed non-specific 
Cbl binding (Fig. 4.9B).  PDGFR association of several other proteins important for PDGFR 
degradation was tested similarily by western blotting: Hrs, Eps15, STAM and tsg101.  After 
several attempts, there was either not enough protein associating with the PDGFR to detect or 
the antibodies were not sensitive enough to detect any of these proteins.  
Lastly, p85 associations with the PDGFR were studied to look for endogenous p85 
associated with the PDGFR and to look for FLAG-p85-wt or FLAG-p85-R274A associated  
Fig. 4.9. Cbl bound non-specifically to the immunoprecipitation beads and/or
the constant regions of the antibodies. Stable cell lines expressing p85 wild type
were stimulated with PDGF for the indicated time.  PDGFR was
immunoprecipitated and samples were resolved using SDS-PAGE.  Western blot
analysis was performed using antibodies specific for Cbl. A) Immunoblot showing
non-specific binding in the rabbit (rb) IgG control. B) Cbl binding was tested using
two different types of immunoprecipitation beads on NIH 3T3 lysates (500 !g) that
were stimulated with PDGF for 10 min.  The control lanes were unstimulated NIH
3T3 cells (25 !g).  Results are representative of two independent experiments.
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with the PDGFR. Anti-p85 and anti-FLAG antibodies were used to probe anti-PDGFR 
immunoprecipitates (Fig. 4.8C).  All p85 proteins were found to be associated with the PDGFR 
after stimulation with PDGF, however p85 proteins remained associated for longer periods of 
time in p85-R274A expressing cells.   
Results from the IP experiment show the PDGFR was still being ubiquitinated in all cell 
lines (Fig. 4.8).  Although Cbl associations could not be determined due to non-specific binding 
to the beads, these data suggested it was not the ubiquitination process that was causing a lack 
of PDGFR degradation seen in cell lines expressing the p85-R274A mutant.   The observed 
results may be due to defects in the sorting process, as the amount of PDGFR was prolonged in 
the p85-R274A expressing cells as compared to control cells.   
These results led to two hypotheses:  i) the decreased PDGFR degradation could be due 
to a lack of receptor endocytosis where the PDGFR would not be taken into the cell via 
endocytosis but would be left on the cell surface to continue signaling and/or ii) the decreased 
PDGFR degradation in p85-R274A expressing cells could be a result of more rapid endosomal 
receptor trafficking.  The p85-R274A mutant has defective RabGAP activity (Chamberlain et 
al., 2004) towards both Rab5 and Rab4, allowing them to remain in their active state longer.  
Thus, Rab5 (PDGFR endocytosis from the plasma membrane) and Rab4 (PDGFR recycling to 
the plasma membrane) may be expected to promote rapid PDGFR endocytosis and recycling 
with reduced opportunities for sorting to a degradative late endosomal/lysosomal pathway.    
 
4.2.2 PDGFR endocytosis as determined by cell-surface biotinylation and uptake 
To test whether or not the PDGFR was being endocytosed, the receptors on the surface 
of the cell were labelled with biotin, induced to endocytose, surface biotin was removed, and 
the internalized receptors were analyzed using strepdavidin IPs and anti-PDGFR 
immunoblotting (Fig. 4.10A).  Sharon Poland, a fellow graduate student in the laboratory, 
performed Biotin Assays on stable cell lines expressing FLAG-p85 wild type, FLAG-p85-
R274A and control NIH 3T3 cells.  Cells were starved for 24 hours and incubated with biotin at 
4°C (on ice) to label surface proteins, but at temperatures that did not allow for receptor  
Fig. 4.10. Increased internalization of PDGFR in cells expressing the RabGAP-
defective p85-R274A mutant.  A) Surface proteins were labeled with biotin and
stimulated with PDGF for the indicated times after which the surface biotin was
stripped off.  Lysates (150 !g) were immunoprecipitated with streptavidin beads to
recover the internalized biotinylated proteins.  B) Samples were resolved by SDS-
PAGE and immunoblotted with PDGFR antibodies.  C) Total cell lysates were
immunoblotted with the PDGFR antibodies to detect total (surface + internalized)
PDGFR levels.  Results are representative of three independent experiments
performed by Sharon Poland.
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endocytosis.  The cells were then stimulated at 37°C for 0, 10, 20, 30, 40, and 60 min with 
PDGF to allow endocytosis of proteins, including the PDGFR.  Cells were placed on ice to halt 
PDGFR trafficking and surface biotin was stripped off using glutathione so only the proteins 
endocytosed would be biotin-labeled.  Biotinylated proteins were immunoprecipitated using 
streptavidin beads and samples were resolved using SDS-PAGE.  Western blot analysis was 
performed using antibodies specific for the PDGFR (Fig. 4.10B).   
There were three controls used in this experiment.  The first was the MOCK (no biotin) 
control.  These cells were not treated with biotin, were unstimulated and kept at 4°C (on ice) 
during the entire experiment.  This control was used to test for any antibody cross-reactivity 
with the IP samples.  There was little or no antibody cross-reactivity seen in any cell line.  The 
second control was the 4°C control.  These cells were treated with biotin and stimulated as long 
as the longest time point of the experiment (60 min), however the cells were kept at 4°C (on 
ice) during the entire experiment.  This control was used to determine the amount of PDGFR 
endocytosis that can occur at 4ºC (on ice) upon PDGF stimulation, when the cells were treated 
at temperatures that should not allow for receptor endocytosis.  There was minimal yet similar 
PDGFR endocytosis seen in all cell lines.  The third control was the 0 min stimulation control.  
These cells were treated with biotin but not stimulated and therefore kept on ice for the entire 
experiment.  This control was used to determine the efficiency of biotin removal from the cell 
surface.   
The levels of the PDGFR were similar in all cell lines (Fig. 4.10B; lysates) and PDGFR 
endocytosis was observed in all cell lines tested (Fig. 4.10B; IP: strepdavidin).  The p85-
R274A expressing cells showed increased levels of internalized PDGFR peaking at 20 min that 
were maintained over the entire time course as compared to control cells (Fig. 4.10B).  As 
another control, total cell lysates were probed for the PDGFR to determine if the PDGFR was 
being degraded throughout the time course (Fig. 4.10B).  There was less degradation seen in 
the p85-R274A cells compared to the control NIH 3T3 cells and p85-wt expressing cells at the 
60 min time point.  The degradation seen was not significant enough to suggest total PDGFR 
levels would influence the amount of PDGFR internalized at the earlier time points.  Results 
suggest PDGFRs are concentrated in an intracellular compartment and the reduced degradation 
of the PDGFR observed in the p85-R274A expressing cells was not the result of PDGFRs 
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trapped at the plasma membrane. 
 
4.2.3 PDGFR trafficking visualized using immunofluorescence and confocal microscopy 
To test whether or not the defective PDGFR degradation in the p85-R274A expressing 
cell line was due to defective endosomal trafficking of the PDGFR, Andrea Hawrysh, a 
research technician in the laboratory, performed a series of coimmunofluorescence experiments 
with control NIH 3T3, p85 wild type, and p85-R274A expressing cells to determine the cellular 
effects of the p85-R274A mutant on PDGFR trafficking through Rab5- and Rab4-containing 
vesicles or compartments.  Rab5 localizes to the early and sorting endosomes where it regulates 
the movement of vesicles containing activated PDGFR from the plasma membrane to sorting 
endosomes.  Rab4 localizes to sorting and recycling endosomes and regulates the movement of 
vesicles containing inactivated PDGFR from the sorting endosomes back to the plasma 
membrane.  Experiments were used to compare the trafficking of PDGFRs in Rab5-positive 
and Rab4-positive vesicles.  Cells were plated in multi-well chamber slides and grown to 60% 
confluency.  Cells were starved overnight and stimulated with PDGF for 0, 10, 30 or 120 min.  
Samples were fixed using paraformaldehyde and permeabilized using saponin.  Cells were 
incubated with antibodies specific for PDGFR, Rab5, Rab4, and phosphotyrosine 857 
(phosphospecific antibody indicative of PDGFR activation; pY857) to assess activation state of 
the PDGFR within these compartments.   
Prior to PDGF stimulation all three cell lines appeared the same (Fig. 4.11-4.14).  There 
was no colocalization between either the PDGFR or the activated PDGFR (pY857) with either 
Rab5-positive or Rab4-positive vesicles.  The three cell lines behaved differently after PDGF 
stimulation.  In comparison to NIH 3T3 cells and the p85-wt expressing cells, PDGFR 
colocalization with Rab5-positive and Rab4-positive vesicles in p85-R274A expressing cells 
were found to colocalize more in intracellular compartments.   
The most notable difference seen between all three cell lines were observed after 30 min 
of PDGF stimulation.  The PDGFR was found to accumulate in intracellular compartments in 
cells expressing the p85-R274A mutant.  The PDGFR partially colocalized to the perinuclear  
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Fig. 4.11. Accumulation of perinuclear Rab5-positive vesicles and peripheral
PDGFR-positive vesicles in p85-R274A-expressing cells stimulated with PDGF
for 30 min.  Control NIH 3T3 (A) cells and cells stably expressing (FLAG-)p85 (B)
or (FLAG-) p85-R274A (C) were stimulated with PDGF for the indicated times, fixed,
permeabilized, and probed with primary antibodies specific for Rab5 and PDGFR.
Secondary antibodies conjugated to Alexa 488 (green) or Alexa 594 (red) were used to
visualize the localization of Rab5 (green) and the PDGFR (red).  Colocalization is
observed as yellow (Both).  The cells were visualized using confocal microscopy.
Note the cells expressing FLAG-p85 are somewhat larger than the other two cell types
are shown 40% smaller to fit into the frame.  D) Selected boxed areas were enlarged
for a more detailed view.  Scale bar, 2 !m for all.  Results are representative of three
independent experiments performed by Andrea Hawrysh.  These experiments were
made possible by access to the confocal microscope by Dr. Mousseau, Dept. of
Psychiatry.
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Fig. 4.12.  Increased perinuclear PDGFR-positive vesicles and partial
colocalization with peripheral Rab4-positive vesicles in cells expressing p85-
R274A. Cells were treated as in Fig. 4.11 and probed to visualize the localization of
Rab4 (green) and the PDGFR (red).  Colocalization is observed as yellow (Both).
Arrows indicate punctate colocalization.  D) Selected boxed areas were enlarged for a
more detailed view.  Scale bar, 2 !m. Results are representative of three independent
experiments performed by Andrea Hawrysh.  These experiments were made possible by
access to the confocal microscope by Dr. Mousseau, Dept. of Psychiatry.
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Fig. 4.13. Colocalization of activated PDGFR (pY857) in Rab5-positive vesicles
within p85-R274A-expressing cells after 30 min of PDGF stimulation.  Cells were
treated as in Fig. 4.11 to visualize the localization of Rab5 (green) and phosphorylated
PDGFR (pY857; indicative of activated PDGFR) (red).  Colocalization is observed as
yellow (Both).  Arrows indicate punctate colocalization. (D) Selected boxed areas
were enlarged for a more detailed view.  Scale bar, 2 !m. Results are representative of
three independent experiments performed by Andrea Hawrysh.  These experiments
were made possible by access to the confocal microscope by Dr. Mousseau, Dept. of
Psychiatry.
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Fig. 4.14. Increased colocalization of activated PDGFR (pY857) in Rab4-positive
vesicles from p85-R274A-expressing cells after 30 min of PDGF stimulation.
Cells were treated as in Fig. 4.11 and probed to visualize the localization of Rab4
(green) and phosphorylated PDGFR (pY857; indicative of activated PDGFR) (red).
Colocalization is observed as yellow (Both).  (D) Selected boxed areas were enlarged
for a more detailed view. Arrows indicate punctate colocalization more prevalent in
p85R274A-expressing cells. Scale bar, 2 !m. Results are representative of three
independent experiments performed by Andrea Hawrysh.  These experiments were
made possible by access to the confocal microscope by Dr. Mousseau, Dept. of
Psychiatry.
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regions in Rab5-positive compartments (Fig. 4.11) and also partially colocalized to the cell 
periphery in Rab4-positive compartments (Fig. 4.12).  The PDGFR was found to localize more 
so in Rab4-positive vesicles than in Rab5 positive vesicles in cells expressing the p85-R274A 
mutant.  The activated PDGFR (pY857) was found to colocalize with both Rab5-positive and 
Rab4-positive vesicles within p85-R274A expressing cells but not in control cells (Fig. 4.13 & 
4.14).  The ability of activated PDGFRs to localize in Rab4-positive recycling vesicles is 
unique to the p85-R274A expressing cells and suggests that receptors are not being 
dephosphorylated prior to recycling.  These observations suggest expression of the p85-R274A 
mutant alters PDGFR trafficking through these Rab5 and Rab4 compartments.  These results 
also suggest cells expressing the p85-R274A mutant perturbs the normal dephosphorylation 
kinetics of the PDGFR. 
 The PDGFR was both endocytosed and ubiquitinated in p85-R274A expressing cells 
suggesting that the lack of sorting to the lysosomal degradation pathway is not the result of 
defective uptake or post translational modifications.  The mechanism of the decreased PDGFR 
degradation displayed by the p85-R274A expressing cells can be attributed to altered PDGFR 
trafficking between endosomal compartments and may also be linked to decreased PDGFR 
dephosphorylation.   
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5.0 DISCUSSION 
5.1 Interaction of p85 with Rab5 
The p85 subunit of PI3K stays associated with the PDGFR during receptor endocytosis 
(Kapeller et al., 1993).  It was suggested that this protein may play a role in regulating PDGFR 
trafficking to a degradative pathway.  Studies have shown that p85 binding sites on specific 
receptors are required for proper receptor down-regulation (Joly et al., 1994).  Mutant PDGFRs 
unable to bind p85 were initially endocytosed as normal but were constitutively recycled and 
not degraded (Joly et al., 1995).  Previous studies have shown p85 was able to interact and bind 
to Rab5, a G-protein which localizes to early and sorting endosomes and regulates the 
movement of vesicles containing activated PDGFR from the plasma membrane to sorting 
endosomes, only when associated with p110" (Christoforidis et al., 1999b).  Chamberlain and 
colleagues have since shown a direct interaction between p85 and Rab5 (Chamberlain et al., 
2004).  The p85 protein contains a BH domain also known as the BCR-homology domain.  It is 
a conserved 200 residue segment within the protein which normally encodes for GAP activity 
toward select G-proteins.  Originally the p85 protein was thought to have no catalytic activity 
but recently has been shown to elicit in vitro GAP activity towards Rab5, Rab4, Cdc42, Rac1, 
and to a lesser extent Rab6 but not Rab11 (Chamberlain et al., 2004).  Typically GAP proteins 
only bind to G-proteins in the active GTP bound conformation but periodically some GAP 
proteins, BNIP-2 and RhoGAP, are able to bind to both the inactive GDP-bound and active 
GTP-bound forms (Low et al., 1999; Self and Hall, 1995).  The p85-wt protein was found to 
bind to both inactive and active conformations of Rab5, whereas some mutant p85 proteins 
were found to bind to the inactive or active conformations, but not both (Chamberlain et al., 
2004). The first objective of this thesis was to characterize the function of the p85:Rab5 
interaction in cells by generating a p85 mutant unable to bind Rab5 by focusing on which 
domains of p85 were needed for Rab5 binding. 
 Several mutant p85 proteins containing different p85 domains expressed alone or in 
combination with other domains were made.  GST pull-down experiments were performed to 
assay the binding interactions between p85 and Rab5.  The interaction between p85 and Rab5 
was identified to be within the BH domain of the p85 protein, the proposed G-protein binding
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site. Mutant proteins missing the BH domain, however, were still able to bind to Rab5 
suggesting there are other domain(s) of p85 involved in Rab5 binding which still need to be 
elucidated.  Some mutant p85 proteins were also selective in their binding and preferred to bind 
to Rab5 in either its GDP-bound or its GTP-bound conformation.  Although future 
experiments, which go beyond the scope of this project, are still needed to fully understand the 
p85 determinants that dictate the binding specificity for Rab5 in the inactive and active 
conformations, the sequential ‘hand-off’ model for how p85 interacts with Rab5 during 
PDGFR endocytosis suggests that p85 could act as a GDF by binding to Rab5-GDP, as well as 
a Rab5 GAP.  
GDF proteins typically interact with GDP-bound G-proteins.  GDFs help to recruit Rab 
proteins to specific membranes by displacing inhibitory GDI proteins.  A three-step GDF 
function model was proposed where a prenylated-Rab-GDI complex was presented to a GDF 
for its membrane recruitment (Pfeffer and Aivazian, 2004).  In this model, it was proposed that 
the Rab-GDI complex would first weakly bind to the GDF protein at the target membrane.  
Secondly, the GDF would release the GDI and bind the prenylated Rab protein.  Third, the 
prenylated Rab protein would be able to insert itself into the target membrane.  It seemed the 
delivery of Rab proteins to their sites of function was selective on the basis of GDF localization 
and further specified by specific Rab5-GTP post-GDF effector protein interactions (e.g. EEA1). 
According to the sequential ‘hand-off’ model, the p85 protein could potentially help to 
recruit Rab5 in its inactive GDP-bound conformation to the early endosome.  The p85 protein 
could function as a GDF using the above three-step GDF function model (Fig. 5.1).  Previous 
GDFs, the neurotrophin receptor p75 and prenylated Rab acceptor-1 protein, have been shown 
to directly associate with membranes through their transmembrane domains (Pfeffer and 
Aivazian, 2004).  Although p85 does not directly interact with endosomal membranes like 
other GDFs, it does stay associated with the activated PDGFR at the plasma membrane and 
during endocytosis. The prenylated-Rab-GDI complex could be presented to p85 at the 
endosomal membrane during PDGFR endocytosis while p85 is complexed with the PDGFR.  
The p85 protein has been shown to interact with Rab5 in its GDP bound conformation and  
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Fig. 5.1 Model of p85 GDF function.  A) The prenylated-Rab-GDI complex is
presented to p85 at the endosomal membrane during PDGFR endocytosis while p85 is
complexed with the PDGFR.  B) The p85 protein facilitates the release of the GDI and
binds the prenylated Rab protein.  C) The prenylated Rab protein inserts itself into the
endosomal membrane where it could then exchange GDP to GTP.
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could facilitate the release of the GDI and bind the prenylated Rab protein.  Lastly, the 
prenylated Rab protein would be able to insert itself into the endosomal membrane, where it 
could then exchange Rab5-GDP to Rab5-GTP, perhaps via the PDGFR-associated Rin1 GEF 
protein (Barbieri et al., 2003) to facilitate membrane fusion events during endocytosis.   
It has also been shown by Chamberlain and colleagues that p85 has GAP activity 
towards select Rab proteins (Chamberlain et al., 2004), however the in vitro GAP activity 
displayed by the p85 protein was dependent upon much higher p85 protein concentrations (%M) 
than what is typically seen by most GAP proteins (nM concentrations).  The sequential “hand-
off” model proposes both p85 and p110" bind Rab5-GTP and the formation of this trimeric 
complex allows the release of p85 from the receptor with a corresponding increase in RabGAP 
activity.  This could suggest that the GAP activity of the p85 protein is further regulated by the 
associated p110 protein (Fig. 5.2).  Typically GAPs provide a catalytic arginine finger and 
stabilize the flexible switch I and switch II regions of the G-proteins in their active GTP-bound 
state.  In some instances, these two functions are carried out by more than one protein and the 
combined contribution of these proteins is necessary for maximal GAP activity.  This appears 
to be the case for the ADP-ribosylation factor (Arf) and ArfGAP.  The GAP activity of 
ArfGAP is increased 10-1000 fold by the presence of a coatomer protein or phospholipids 
(Goldberg, 1999); (Szafer et al., 2000).  This is also the case for RanGAP where the GAP 
activity is influenced by Ran binding proteins (Seewald et al., 2002; Seewald et al., 2003).  
Since p85 possess an important R274 residue, this likely corresponds to the arginine finger and 
it may be that p110 binds to Rab5-GTP and stabilizes the switch regions to accelerate the 
GTPase activity of Rab5.   
We hypothesize that p85 acts both as a GDF and a GAP towards Rab5 and potentially 
to other Rab proteins such as Rab4.  Further studies will need to be conducted to fully 
understand the p85:Rab5 interaction in cells and to further investigate p85 interactions with 
other Rab proteins. 
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Fig. 5.2. The p85:p110 interaction with Rab5-GTP may stimulate the GTPase
activity of Rab5. The GAP activity of the p85 protein may be further regulated by
the association of the p110 protein.  The p85 protein possess an important R274
residue which likely corresponds to the catalytic arginine finger of GAP proteins and
it may be that p110 binds to Rab5-GTP and stabilizes the switch regions to accelerate
the GTPase activity of Rab5.
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5.1.1 Future work to determine the mechanism of Rab regulation by p85 
 The sequential ‘hand-off’ model for how p85 interacts with Rab5 during PDGFR 
endocytosis suggests that p85 could act as a GDF and a GAP towards Rab5.  It suggests the 
additional binding of p110" to p85:Rab5-GTP increases the p85 RabGAP activity to facilitate 
GTP hydrolysis.  A series of experiments have been proposed by our laboratory to help us 
better understand the role of p85 in Rab protein regulation.   
 To begin, we would like to better understand the p85:Rab5 interaction.  There are two 
ways we are planning to do this: i) by measuring the binding affinities and GAP activities of 
p85:Rab5 complexes, and ii) by determining the crystal structure of the p85:Rab5 complex.  
Measuring the binding affinity constant, the “on” rate, and the “off” rate for several p85:Rab 
complexes, including Rab5, will be made possible using the BIACORE system located in the 
Structural Sciences Center at the University of Saskatchewan.  A sensor chip will be made with 
chemically attached anti-GST antibodies.  GST-Rab5-S34N and GST-Rab5-Q79L along with 
GDP + Mg
2+
 and GTP + Mg
2+
, respectively, will be immobilized onto separate chips and 
purified p85 proteins will be allowed to flow over the chips where the binding affinities will be 
measured.  We expect to see intermediate affinities between both p85:Rab5-GTP and 
p85:Rab5-GDP with the highest binding affinity seen between p85:p110":Rab5-GTP.  To 
determine the p85 structure/function relationship, in collaboration with Dr. Louis Delbaere 
(Canada Research Chair, Dept. of Biochemistry, University of Saskatchewan), the crystal 
structure of p85 complexes with phosphopeptide (to mimic the phosphorylated PDGFR), Rab5-
S34N, Rab5-Q79L, Rab4-S27N and Rab4-Q72L will be determined.  Information concerning 
the structure of these protein complexes will allow us to determine the residues important for 
binding, as well as the mechanism of Rab5 and Rab4 GTPase stimulation by p85. 
 To test the possible GDF function of p85 in Rab5 membrane recruitment, we will 
generate a p85-BH domain mutant which is unable to bind to Rab5 to determine if this mutant 
can disrupt Rab5 membrane recruitment and PDGFR trafficking.  Mutagenesis experiments 
will be used to target residues responsible for Rab5 binding (as determined by the crystal 
structure) and pull-down experiments will be used to determine Rab5 binding or lack of 
binding.  If p85 is a GDF, cells expressing this p85-BH mutant unable to bind Rab5 would be 
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defective in PDGFR endocytosis, resulting in PDGFR accumulation at the plasma membrane 
and increased downstream signalling, and Rab protein accumulation in the cytosol, unable to 
become membrane bound. 
 Finally, to investigate if p110" has an effect on p85 RabGAP activity, as suggested by 
our “hand-off” model, we will perform a series of GAP assays titrating different concentrations 
of p85:p110" with Rab5 and Rab4.  We will compare these results with those from control 
GAP assays using only purified p85 protein.  Our model predicts the p85:p110" will be able to 
increase the GTPase activity of both Rab5 and Rab4 at lower concentrations of purified 
p85:p110" added as compared to control p85 alone.  To emulate the phosphorylated PDGFR, 
we will also perform GAP assays with phosphopeptide and control peptide to induce the 
PDGFR-bound conformation of p85 to see what effect this has on GAP activity.  Our model 
suggests the GAP activity of p85 is increased when the trimeric p85:p110":Rab-GTP complex 
is released from the PDGFR, therefore assays performed in the presence of phosphopeptide 
may show reduced GAP activity for both the p85:p110" complex and p85 alone. 
Taken together, these experiments will allow us to better understand how Rab5 and 
Rab4 regulate PDGFR activation state, downstream signalling and trafficking through the 
endocytic pathway during PDGFR endocytosis.  These experiments will also help us to 
understand the role of p85 binding and GAP activity within these complex processes.  We will 
be able to improve our understanding of the sequence of events which co-ordinate and regulate 
the activities responsible for normal PDGFR trafficking within cells. 
 
5.2 Model as to the mechanism of defective PDGFR degradation in cells expressing the 
p85-R274A mutant 
The PDGFR is one of many growth factor receptors responsible for controlling 
numerous cellular processes such as proliferation, differentiation, and cell survival 
(Schlessinger, 2000).  A process known as endocytosis is responsible for the down-regulation 
of this growth factor receptor.  If there is a defect in this down-regulation pathway, there is 
defective PDGFR degradation and the PDGFR continues to signal for much longer periods of 
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time than what is normally allowed.  This prolonged signalling can result in excess cell growth 
and cellular survival leading to cancerous properties.  The p85-R274A mutant contains a point 
mutation within its BH domain rendering it inactive for in vitro GAP activity towards Rab 
proteins (Chamberlain et al., 2004).  NIH 3T3 cells expressing this p85 mutant have increased 
and prolonged PDGFR activation as well as decreased PDGFR degradation.  Recent evidence 
shows cells stably expressing p85-R274A can form tumors in nude mice (Chamberlain et al., 
2008).  In response to PDGF stimulation, the p85-R274A mutation did not alter its ability to 
bind to and regulate p110-PI3K activity (Chamberlain et al., 2004) thereby suggesting the 
effects of this mutant are independent of PI3K activity.  The second objective of this thesis was 
to determine the mechanism of defective PDGFR degradation in cells expressing the p85-
R274A mutant.  In the case of the p85-R274A expressing cells, there were three aspects of 
receptor down-regulation that were studied to determine the mechanism of defective PDGFR 
degradation.  These aspects were: i) PDGFR ubiquitination, ii) PDGFR endocytosis and iii) 
PDGFR trafficking. 
The first aspect studied was whether or not the PDGFR was ubiquitinated.  Studies have 
shown the PDGFR is monoubiquitinated and this signal is sufficient for endocytosis and 
degradation (Haglund et al., 2003).  The monoubiquitination signal is involved in PDGFR 
trafficking for lysosomal sorting steps, thereby preventing receptor recycling (Marmor and 
Yarden, 2004).  Studies have shown defects in the ubiquitination process decrease RTK 
internalization and sorting, resulting in oncogenesis (Peschard and Park, 2003).  PDGFR IPs 
were performed after PDGF stimulation and the IP samples were probed for ubiquitin, along 
with other proteins involved in the ubiquitination process.  Results confirmed that the PDGFR 
was indeed ubiquitinated and the defective PDGFR degradation was not due to a lack of 
degradative sorting signals (Fig. 4.8). 
Next PDGFR endocytosis was studied to determine if the PDGFR was being 
internalized or accumulating at the plasma membrane.  Studies have shown aberrant RTK 
internalization or overexpression of receptors at the plasma membrane lead to oncogenesis and 
gene amplification, increased gene expression, and defects in receptor trafficking and 
degradation can result in RTK overexpression (Dikic and Giordano, 2003; Peschard and Park, 
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2003; Thien and Langdon, 2001).  Biotin was used to label the PDGFR on the cell surface.  The 
cells were induced to endocytose the PDGFR by PDGF stimulation and the internalized biotin-
labelled PDGFR was isolated from cell lysates.  These experiments clearly showed that the 
PDGFR was being internalized in cells expressing the p85-R274A mutant (Fig. 4.10B).   
The PDGFR was both ubiquitinated and endocytosed by the cell suggesting the PDGFR 
should have been degraded normally, providing there were no defects in PDGFR trafficking 
from the plasma membrane to the lysosome. Therefore PDGFR trafficking was studied using 
immunofluorescence experiments.  The p85-BH domain contains in vitro GAP activity towards 
Rab5 and Rab4, proteins which regulate the entry of vesicles to the early endosome and the exit 
of vesicles back to the plasma membrane via recycling endosomes respectively.  This suggests 
the possibility that expression of this mutant may deregulate Rab5 and Rab4 function and 
disturb Rab-mediated PDGFR trafficking.  Immunofluorescence experiments looked at the 
colocalization of Rab5 and Rab4 with either the PDGFR or pY857 PDGFR.   
A model as to the mechanism of defective PDGFR degradation in cells expressing the 
p85-R274A mutant was proposed from the results obtained (Fig. 5.3 and Fig. 5.4).  Results 
(Fig. 4.11-4.14) suggest reduced PDGFR-associated-p85-R274A-encoded RabGAP activity 
initially resulted in increased Rab5-GTP-driven membrane fusion and rapid PDGFR 
endocytosis as well as increased Rab4-GTP-driven membrane fusion and rapid PDGFR 
recycling back to the plasma membrane (Fig. 5.3).  The lack of GAP activity of the p85-R274A 
mutant was unable to contribute to and accelerate Rab5 and Rab4 GTP hydrolysis and over 
time this could result in Rab protein sequestration on intracellular membranes (Fig. 5.4).  The 
Rab5-GTP protein accumulated on perinuclear early/sorting endosomal membranes and the 
Rab4-GTP protein accumulated on peripheral vesicles which may correspond to recycling 
endosomes.  The net result was blocked PDGFR trafficking, which prevented normal PDGFR 
dephosphorylation and degradation, attributed to a lack of sufficient cytosolic Rab5-GDP and 
Rab4-GDP required to associate with new membranes and facilitate additional vesicle fusion 
events. 
The effects seen by cells expressing the p85-R274A mutant seem to be specific for the  
Fig. 5.3. Cells expressing the p85-R274A mutant show increased rates of PDGFR
endocytosis and recycling.  Reduced PDGFR-associated-p85-R274A-encoded
RabGAP activity initially results in increased Rab5-GTP-driven membrane fusion and
rapid PDGFR endocytosis as well as increased Rab4-GTP-driven membrane fusion
and rapid PDGFR recycling back to the plasma membrane as compared to control
cells.
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Fig. 5.4. Model as to the mechanism of defective PDGFR degradation in cells
expressing the p85-R274A mutant.  Reduced PDGFR-associated-p85-R274A-
encoded RabGAP activity initially resulted in increased Rab5-GTP-driven membrane
fusion and rapid PDGFR endocytosis and increased Rab4-GTP-driven membrane
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recycling endosomal membranes.  This results in C) a lack of sufficient cytosolic
Rab5-GDP and D) a lack of cytosolic Rab4-GDP required to associate with new
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p85 subunit of PI3K.  PDGFRs lacking p85 binding sites are able to internalize but are 
constitutively recycled rather than degraded (Joly et al., 1994), while PDGFR with mutated 
binding sites for other signalling proteins (RasGAP and PLC#1) are degraded as normal.  It is 
possible that that there is a decrease of PI3K lipid products which are known to play critical 
roles in membrane fusion events.  The lack of lipid products could prevent vesicle fusion 
events; however, there are several PI3K families responsible for generating these lipid products 
and it is unknown if vesicle fusion events would be blocked in these cells as well.  Our model 
predicts that the lack of p85:Rab5 associations and decreased RabGAP activity would block 
PDGFR degradation.  Our model predicts cells would have an increased rate of internalization 
and recycling.  As shown previously, the decreased time the receptor stays in the early sorting 
endosome, reduces the chance for it to be targeted to the degradative pathway (Mayor et al., 
1993).  This lack of receptor degradation seems to be independent of normal PI3K activity, as 
expression of a p110! mutant defective for PI3K catalytic activity did not prevent EGFR 
endocytosis or degradation (Chen and Wang, 2001).  The effects seem to be specific for the p85 
subunit and contribute to the increasing knowledge and evidence of this protein having 
regulatory functions beside those involving p110!. 
 
5.2.1 Future experiments to characterize the mechanism of receptor trafficking using p85-
R274A expressing cells 
 Our model as to the mechanism of defective PDGFR degradation in cells expressing the 
p85-R274A mutant suggests Rab5 and Rab4 are sequestered on endosomal membranes.  
Because of this sequestration, PDGFRs are not properly trafficked through the endocytic 
pathway and are retained inside cells longer and are not degraded as quickly.  Our lab will use 
complimentary biochemical and cell biology methods to test and monitor PDGFR trafficking. 
 Rabaptin5 is a protein which selectively binds the active GTP-bound conformations of 
Rab5 and Rab4.  GST-Rabaptin5 pull-down experiments will be used to measure cellular levels 
of Rab5-GTP and Rab4-GTP from cell lysates after 0 and 30 min PDGF stimulation.  Our 
model predicts cells expressing p85-R274A will have higher levels of Rab5-GTP and Rab4-
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GTP after 30 min of PDGF stimulation due to Rab protein sequestered on endosomal 
membranes. 
 Subcellular fractionation experiments will be used to determine the membrane versus 
cytoplasmic location of Rab5 and Rab4 after PDGF stimulation.  Cell lysates will be 
fractionated into membrane and cytosolic fractions, and intracellular organelle fractions.  
According to our model, an abundance of Rab5 and Rab4 should be found in the membrane 
fraction, the intracellular fraction, and found on early endosome (Rab5) and recycling 
endosomal (Rab4) organelle fractions in cells expressing the p85-R274A cells. 
 Lastly, we will use confocal microscopy and fluorescence recovery after 
photobleaching (FRAP) experiments to define the type of endosomal compartments perturbed 
in p85-R274A expressing cells.  FRAP experiments, done in collaboration with Dr. Heidi 
McBride (Ottawa Heart Institute), will be used to track cyan fluorescent protein (CFP)-Rab5 
and CFP-Rab4 membrane recovery rates after photobleaching the membrane-associated Rab 
protein on a vesicle in live cells.  Our model predicts that when we express abundant CFP-Rab 
protein to provide a large cytoplasmic pool, cells expressing p85-R274A will show enhanced 
rates of fluorescence recovery after photobleaching because the CFP-Rab proteins will be 
moving from the cytoplasm to the vesicle membrane but will be trapped on the membrane in 
the GTP-bound form.  In contrast, in control cells there will be less fluorescence recovery after 
photobleaching because the CFP-Rab proteins will be able to cycle off the membrane normally. 
These experiments will allow us to identify where key proteins within the endocytosis 
pathway are located.  In cell expressing the p85-R274A mutant, these experiments will allow us 
to determine the point(s) in the endocytosis pathway which is being disrupted and how the Rab 
proteins and p85 are responsible for this disruption.  We will gain a better understanding of the 
events which dictate normal PDGFR trafficking within cells by first understanding the events 
responsible for disrupting it. 
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6.0 CONCLUSIONS 
We have shown p85 may be responsible for regulating PDGFR endocytosis by 
contributing to the recruitment and deactivation of Rab proteins.  The p85 protein is able to 
interact with Rab5 through its BH domain and may act as a GDF to help target Rab5 to the 
appropriate endosomal membrane where it would become activated to facilitate membrane 
fusion events during receptor endocytosis.  The p85 RabGAP activity is also responsible for 
deactivating Rab5 by accelerating Rab5 GTPase activity resulting in Rab5 inactivation and 
decreased vesicle fusion events during receptor endocytosis.  A p85-R274A mutant defective 
for RabGAP activity clearly alters PDGFR trafficking during receptor endocytosis and cells 
expressing this mutant display increased PDGFR activation and decreased degradation.  We 
have proposed a model for this defective trafficking where the net result was blocked PDGFR 
trafficking, which prevented normal PDGFR dephosphorylation and degradation, attributed to a 
lack of sufficient cytosolic Rab5-GDP and Rab4-GDP required to associate with new 
membranes and facilitate additional vesicle fusion events.  This model helps to explain why 
cells expressing the p85-R274A mutant form tumors in nude mice.  The lack of lysosomal 
targeting, allows the receptor to be sequestered in cells but still have the ability to signal as the 
receptor would not be targeted to the MVB were signalling is abolished. 
As the overlap between the molecular mechanisms of endocytosis and signalling 
becomes evident, more work is needed to untangle the regulatory networks and shed light on 
how the processes influence each other and cellular proliferation (Bache et al., 2004).  It is 
becoming clear that the downregulation of RTKs by endocytosis and lysosomal sorting 
represents a key mechanism for signal termination.  The experimental results outlined in this 
thesis give us a better understanding of a small part of this process and the proteins which are 
involved.  Further exploration into this process is needed to fully understand its complexity and 
to understand how to manipulate this process for therapeutic intervention. 
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